Multiomics integrative analysis identifies APOE allele-specific blood biomarkers associated to Alzheimer’s disease etiopathogenesis

Laura Madrid1, Sonia Moreno-Grau2,3, Shahzad Ahmad4, Antonio González-Pérez1, Itziar de Rojas2,3, Rui Xia5, Pamela V. Martino Adami6, Pablo García-González2, Luca Kleinediam6,7,8, Qiong Yang9, Vincent Damotte10, Joshua C. Bis11, Fuensanta Noguera-Perea12, Céline Bellenguez10, Xueqiu Jian5, Juan Marín-Muñoz12, Benjamin Grenier-Boley10, Adela Orellana2,3, M. Arfan Ikram4, Philippe Amouyel10, Claudia L. Satizabal13,14, Alzheimer’s Disease Neuroimaging Initiative (ADNI)1, EADI consortium, CHARGE consortium, GERAD consortium, GR@ACE/DEGESCO consortium, Luis Miguel Real15,16, Carmen Antúnez-Almagro12, Anita DeStefano7,14, Alfredo Cabrera-Socorro17, Rebecca Sims18, Cornelia M. Van Duijn4, Eric Boerwinkle19, Alfredo Ramírez6,7,8, Myriam Fornage5, Jean-Charles Lambert10, Julie Williams18,20, Sudha Seshadri13,14, ADAPTED consortium, Janina S. Ried21, Agustín Ruiz2,3, Maria Eugenia Saez1

1Andalusion Bioinformatics Research Centre (CAEBi), Sevilla, Spain
2Research Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain
3CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
4Department of Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
5Institute of Molecular Medicine and Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
6Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany
7Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
8German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
9Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
10University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque Et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France
11Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98195, USA
12Unidad de Demencias, Hospital Clínico Universitario Virgen de la Arrixaca, Carretera de Madrid-Cartagena s/n, 30120 El Palmar, Murcia, España
13Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX 78229, USA
14Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA
15Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Sevilla, Spain
16Department of Surgery, Biochemistry and Immunology, University of Malaga, Spain
17Janssen Research and Development, a Division of Janssen Pharmaceutica N.V., Beerse, Belgium
18Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK
19Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
20UKDRI@Cardiff, School of Medicine, Cardiff University, Cardiff, UK
21AbbVie Deutschland GmbH & Co. KG, Genomics Research Center, Knollstrasse, Ludwigshafen, Germany
Alzheimer’s disease (AD) is the most common form of dementia, currently affecting 35 million people worldwide. Apolipoprotein E (APOE) ε4 allele is the major risk factor for sporadic, late-onset AD (LOAD), which comprises over 95% of AD cases, increasing the risk of AD 4-12 fold. Despite this, the role of APOE in AD pathogenesis is still a mystery. Aiming for a better understanding of APOE-specific effects, the ADAPTED consortium analyzed and integrated publicly available data of multiple OMICS technologies from both plasma and brain stratified by APOE haplotype (APOE2, APOE3 and APOE4). Combining genome-wide association studies (GWAS) with differential mRNA and protein expression analyses and single-nuclei transcriptomics, we identified genes and pathways contributing to AD in both APOE dependent and independent fashion. Interestingly, we characterized a set of biomarkers showing plasma and brain consistent protein profiles and opposite trends in APOE2 and APOE4 AD cases that could constitute screening tools for a disease that lacks specific blood biomarkers. Beside the identification of APOE-specific signatures, our findings advocate that this novel approach, based on the concordance across OMIC layers and tissues, is an effective strategy for overcoming the limitations of often underpowered single-OMICS studies.

INTRODUCTION

Non-Mendelian Alzheimer’s disease (AD) has become the paradigm of a complex disease for which a major genetic determinant is known, the APOE locus. Three linkage studies published in 1993 pointed to the APOE region at 19q13 as a risk locus for late onset familial AD [1, 2], and even common sporadic late-onset AD (LOAD) [3]. Shortly after, researchers around the world confirmed the association of APOE gene with diverse forms of the disease and its association with other dementias.

The APOE gene encodes a lipoprotein firstly identified in the 1970s among patients with familial hypercholesterolemia type III [4, 5]. The protein has three major isoforms depending on the combination of two polymorphisms located at positions 112 (rs429358 (C > T)) and 158 (rs7412 (C > T)). The most common isoform, APOE3, has a cysteine at position 112 and an arginine at position 158, whereas APOE2, the least common isoform, has a cysteine at both positions, and the AD risk allele APOE4 has an arginine at both positions [6–8]. These aminoacidic substitutions result in a conformational change that brings together the N-terminal and C-terminal domains in APOE4, which are normally separated in APOE2 and APOE3 isoforms. The consequences in downstream signaling of this conformational shift in the APOE4 isoform are still unknown. In fact, it is not even clear if the APOE4 is a gain or loss of function mutation despite extensive research in the field [9]. What is already known is that having a single APOE4 allele increases risk 2- to 4-fold and having two APOE4 alleles increases risk about 8- to 12-fold, although risk varies according to genetic background and sex [10].

In the last years, genome-wide association studies (GWAS) have contributed a number of Alzheimer’s disease associated low penetration genes, including ABCA7, AB13, ACE, AC074212.3, ADAM10, ADAMTS1, ADAMTS4, ALPK2, ANKDR31, APH1B, ATPSH, B1N1, BZRAP1-AS1, CASS4, CD2AP, CD33, CELF1-MADD, CLNK, CLU, CNTNP2, CR1, DSG2, ECHDC3, EPHA1, FERMT2, HEX1, HLA-DRB5–HLA-DRB1, HS3ST1, KAT8, IQCK, INPP5D, NME8,
NYAP1, MS4A gene cluster, NDUFA6, OARD1, PICALM, PLCG2, PTK2B, SCIMP, SLC24A4, SORL1, SPI1, TREM2, WWOX, ZCWPW1 [11–14]. Some reports have performed stratified analyses based on the presence or absence of the APOE4 allele, identifying some additional genes with effect in APOE4 carriers (such as ISYNA1, CUGBP2) or in individuals lacking the E4 allele (AC099552, GPAA1, MAPT, NSF, TREM2) [15–18].

One aim of the ADAPTED consortium is to identify specific APOE signatures associated with the different APOE isoforms. We describe for the first time herewith a comprehensive integration of genomic, transcriptomic and proteomic data stratified by the three major APOE haplotypes.

**RESULTS**

**GWAS data: SNP-level analysis**

The combined analysis of the three stages (stage I+II+III) (Figure 1 and Supplementary Tables 1–3 and Supplementary Figures 1–3), identified genome-wide significant signals (p<5x10⁻⁸) for APOE, BIN1, CLU, CNTNAP2 and PICALM in the APOE4 stratum; suggestive signals (p<10⁻⁵) in this analysis include a 1.4Mb intergenic region on 4p15. (from 33.3Mb to 34.7Mb, hg19) with lowest p value for the SNP rs12641122 (p=6.28x10⁻⁷), a 4.5Kb intergenic region on 4q35.2 or the KCNQ3 gene among others. In the APOE3 stratum, ABCA7, BIN1 and PICALM passed the genome-wide significance threshold, with suggestive signals for the HLA-DQ/HLA-DR loci, CTNND2, FBN1, WLS or CSTF1 genes among others. By contrast, no genome wide significant SNPs were found in the APOE2 stratum, nor any known AD gene among suggestive signals.

An additional validation of stage I+II+III findings was performed using the EADI population (stage IV), where only the APOE locus in the APOE4 stratum reached the genome wide significance threshold (Supplementary Figure 4). In the combined analysis of Stage I+II+III and Stage IV results, ABCA7, BIN1 and PICALM in the APOE3 stratum and APOE, BIN1, CLU and PICALM in the APOE4 stratum reached genome-wide significance (Supplementary Tables 4–6 and Supplementary Figure 5).

![Figure 1](image-url). Manhattan and QQ plots of stage I+II+III APOE2 (A, D), APOE3 (B, E) and APOE4 (C, F) stratified meta-analysis.
Sex stratified meta-analysis (Supplementary Tables 7, 8 and Supplementary Figure 6) identified genome-wide significant signals for BNI1 and APOE as well as suggestive signals for PICALM, MYLK, SOX5 and SCEL in the female population. By contrast in males, only suggestive signals for BIN1, APOE, ZCCHC2, the ABI3BP/IMPG2 locus, ESRRB and the 19q13.4 leucocyte receptor cluster were identified. Stratified analysis by sex and APOE (Supplementary Tables 9–14 and Supplementary Figure 7), yielded genome-wide significant signals for APOE in the APOE4 stratum in both sexes and for a 400kb 13q31.3 intergenic region containing the Ubiquitin Specific Peptidase 7 (Herpes Virus-Associated) (USF7) pseudogene (RP11-464I4.1) for APOE3 males. Among APOE4 males, we found association with AD for a large region of 1.9Mb on 3q12.1 comprising the genes CMSS1, COL8A1, FILIP1L, MIR548G, RPL24 and, in females, a 1.5Mb region on 2q33.2 comprising the ABI3 homologue ABI2, CARF, CYP20A1, FMN17B, FZD7, ICA1L, NBEAL1, RAPH1 and WDR12 genes.

GWAS data: gene-level analysis

Genetic marker-level results were summarized into a single measure of association for each gene. Then, association results from the combined stage I, II and III meta-analysis were used to estimate gene-wide statistics for all genes in each one of the three APOE strata (Supplementary Tables 15–17). Per stratum, genes were ranked in ascending order according to lowest to highest p values derived from the mean χ2 statistics implemented in MAGMA (Table 1). Among previously reported AD genes, APOE was the highest ranked in both APOE2 and APOE4 carriers (ranks 26 and 3 respectively), whereas BIN1 was ranked first in the APOE3 stratum (Supplementary Table 18). Known AD genes were ranked worst in the APOE2 stratum than in the others, with the complement receptor 1 (CRI), ranked in position 1292, being the second most relevant of these genes among APOE2 carriers after APOE.

Differential expression analysis

Blood APOE stratified DE meta-analysis between AD cases and controls (Supplementary Tables 19–21) included the ADNI and ADDN datasets. In the APOE2 stratum we identified only two upregulated (ISY1 and SRF) and two downregulated (CPTIA, PLCD1) genes below the FDR <0.05 threshold, clearly differing from expression profiles in APOE3 and APOE4 carriers (Figure 2, top 100 genes from each stratum). By contrast, APOE3 and APOE4 stratified analyses identified 1,692 and 3,293 DE genes respectively. Among genes differentially expressed in APOE4 cases versus controls we observed an over-representation of mitochondrial genes, most of them involved in the oxidative phosphorylation pathway. However, several genes from this pathway were differentially expressed in all strata but with opposite expression profiles, such as the electron transport chain genes ATP5F1, UQCRB or NDUFB3 upregulated in APOE2 cases but downregulated in APOE4 cases when compared to controls of the same haplotype. APOE3 genes were mainly cytoplasmatic genes involved in RNA metabolism.

Cortex APOE-stratified DE included the MAYO, ROSMAP, MSBB, GSE15222 and GSE48350 studies. Meta-analysis of cortex datasets resulted in 518, 7714 and 1717 statistically significant genes (FDR<0.05) for the APOE2, APOE3 and APOE4 strata respectively (Supplementary Tables 22–24). As opposed to blood analyses, the overall picture is of enhanced gene expression in AD in all strata, but more pronounced in APOE2 except for XIST, strongly downregulated in AD APOE2 subjects (Figure 3, top 100 genes from each stratum). The heparan sulfate proteoglycan CD44 and the heparan sulfate lysosomal degradation enzyme IDS encoding genes were differentially expressed in all strata, with CD44 strongly upregulated in APOE2 cases and IDS downregulated in APOE4 cases. APOE2 specific genes were mostly nuclear genes involved in primary metabolic processes, as well as some apoptosis related genes (CFLAR, ATM, MCL1, AKT3 and CTSS), all of them downregulated in AD cases but CTSS, with higher expression in AD cases than in controls. APOE3 and APOE4 candidate genes were mainly expressed in the cytoplasm. In all strata, we identified genes involved in neuronal development (such as GFAP, BDNF or CDC42), especially in the APOE3 stratum. For both APOE2 and APOE4 strata, genes involved in vesicle mediated transport were identified, with key genes such as PCSK1, SYT12 or SVOP downregulated in APOE4 cases.

Robust rank aggregation analysis

Integrative analysis was performed independently to include either blood or cortex APOE-stratified DE rankings. Thus, we combined meta-GWAS stage I-III gene-level results with blood meta-GWES results (Supplementary Tables 25–27) or with cortex meta-GWES results respectively (Supplementary Tables 28–30).

In blood 275, 284 and 278 genes passed the FDR threshold in the APOE2, APOE3 and APOE4 strata respectively with 15 common genes, associated with AD irrespective of the APOE haplotype, which include APOC1, CLPTM1, DNAAJ1, ING3, LARP7, NGDN, RPA3, RPL36AL, RPS24, SOD1, SRP19, and four
| Rank E2 | HUGO     | NSNPS | NPARAM | Z_STAT | Pjoint  | PSNPwise (mean) | PSNPwise (top) |
|--------|----------|-------|--------|--------|----------|-----------------|----------------|
| 1      | LRRC37A  | 120   | 17     | 3.83   | 6.29E-05 | 2.99E-05        | 1.14E-03       |
| 2      | TOMM40   | 193   | 18     | 3.79   | 7.59E-05 | 3.34E-05        | 1.32E-03       |
| 3      | CCDC78   | 115   | 17     | 3.81   | 6.99E-05 | 3.68E-05        | 1.14E-03       |
| 4      | DUOX2    | 145   | 23     | 3.63   | 1.41E-04 | 3.68E-05        | 6.05E-03       |
| 5      | HAGHL    | 107   | 15     | 3.83   | 6.43E-05 | 3.88E-05        | 9.08E-04       |
| 6      | NARFL    | 105   | 15     | 3.83   | 6.51E-05 | 4.00E-05        | 8.92E-04       |
| 7      | STUB1    | 193   | 18     | 3.72   | 1.01E-04 | 4.61E-05        | 1.56E-03       |
| 8      | ABCB4    | 344   | 35     | 3.89   | 5.11E-05 | 5.27E-05        | 5.59E-03       |
| 9      | APOC1    | 209   | 32     | 3.42   | 3.16E-04 | 5.40E-05        | 4.13E-02       |
| 10     | IRGC     | 300   | 45     | 4.55   | 2.72E-06 | 5.52E-05        | 3.36E-05       |

| Rank E3 | HUGO     | NSNPS | NPARAM | Z_STAT | Pjoint  | PSNPwise (mean) | PSNPwise (top) |
|--------|----------|-------|--------|--------|----------|-----------------|----------------|
| 1      | BIN1     | 633   | 70     | 7.02   | 1.15E-12 | 8.93E-07        | 3.51E-12       |
| 2      | FBN1     | 533   | 41     | 4.71   | 1.27E-06 | 4.82E-06        | 2.76E-04       |
| 3      | WNT3     | 239   | 38     | 4.69   | 1.35E-06 | 6.85E-06        | 1.26E-04       |
| 4      | CLEC4M   | 424   | 68     | 4.07   | 2.35E-05 | 1.35E-05        | 1.46E-03       |
| 5      | NSF      | 144   | 22     | 4.76   | 9.48E-07 | 2.88E-05        | 3.07E-05       |
| 6      | CASS4    | 349   | 50     | 5.00   | 2.80E-07 | 3.43E-05        | 4.58E-05       |
| 7      | APP      | 998   | 99     | 3.96   | 3.75E-05 | 3.91E-05        | 3.43E-03       |
| 8      | GPR27    | 306   | 47     | 3.21   | 6.62E-04 | 4.63E-05        | 6.29E-02       |
| 9      | CRHR1    | 1261  | 23     | 4.07   | 2.39E-05 | 5.46E-05        | 2.55E-03       |
| 10     | CD209    | 482   | 71     | 3.80   | 7.36E-05 | 6.93E-05        | 1.55E-03       |
| 11     | SPPL2C   | 556   | 19     | 4.03   | 2.83E-05 | 7.77E-05        | 1.68E-03       |
| 12     | KANSL1   | 978   | 20     | 4.01   | 2.98E-05 | 7.79E-05        | 1.44E-03       |
| 13     | LRRC37A  | 115   | 6      | 4.01   | 3.09E-05 | 7.97E-05        | 4.41E-04       |
| 14     | STH      | 460   | 17     | 3.94   | 4.00E-05 | 8.35E-05        | 2.88E-03       |
| 15     | EIF4E3   | 516   | 83     | 3.01   | 1.29E-03 | 9.34E-05        | 1.41E-01       |

| Rank E4 | HUGO     | NSNPS | NPARAM | Z_STAT | Pjoint  | PSNPwise (mean) | PSNPwise (top) |
|--------|----------|-------|--------|--------|----------|-----------------|----------------|
| 1      | TOMM40   | 293   | 44     | 14.90  | 1.59E-50 | 1.50E-26        | 1.00E-50       |
| 2      | APOC1    | 247   | 38     | 15.05  | 1.71E-51 | 3.20E-26        | 1.00E-50       |
| 3      | APOE     | 270   | 40     | 14.82  | 5.36E-50 | 2.83E-24        | 1.00E-50       |
| 4      | PVRL2    | 361   | 51     | 14.31  | 8.88E-47 | 1.17E-23        | 1.00E-50       |
| 5      | APOC4    | 241   | 29     | 11.30  | 6.96E-30 | 1.60E-14        | 2.52E-33       |
| 6      | APOC2    | 232   | 27     | 13.20  | 4.31E-40 | 8.54E-13        | 1.00E-50       |
| 7      | CLPTM1   | 267   | 34     | 12.78  | 1.06E-37 | 3.43E-11        | 5.65E-46       |
| 8      | CLU      | 351   | 46     | 7.60   | 1.47E-14 | 5.85E-10        | 4.89E-13       |
| 9      | SCARA3   | 426   | 51     | 7.08   | 7.06E-13 | 7.15E-07        | 3.53E-13       |
| 10     | PICALM   | 555   | 43     | 5.54   | 1.49E-08 | 8.39E-07        | 9.65E-08       |
| 11     | AKAP2    | 601   | 85     | 4.12   | 1.86E-05 | 2.27E-06        | 5.58E-03       |
| 12     | PALM2-AKAP2 | 1542   | 159   | 3.61   | 1.52E-04 | 3.72E-05        | 1.46E-02       |
| 13     | IL6      | 414   | 48     | 3.72   | 1.01E-04 | 4.36E-05        | 7.17E-03       |
| 14     | EPHX2    | 467   | 56     | 4.23   | 1.15E-05 | 5.26E-05        | 2.17E-04       |
| 15     | BIN1     | 635   | 70     | 5.70   | 5.95E-09 | 5.72E-05        | 1.11E-08       |
Figure 2. Top candidates from DE analysis in blood datasets.
Figure 3. Top candidates from DE analysis in cortex datasets.
mitochondrial proteins (ATP5F1, ATP6V1D, MRPL51 and UQCRH). The list of APOE2 specific genes is the largest one (241 genes) and include mitochondrial transporters such as SLC25A3 and SLC25A4. APOE3 specific signatures included MAPT and APP genes, along with other neuronal genes such as the cholinergic receptors CHRNA10 and CHRNA2. APOE4 specific genes included known AD genes involved in vesicle transport such as CLU and SORL1; SORL1 has been shown to regulate IL6 levels, also identified among APOE4 specific signatures. We found however a large overlap among significant genes for the APOE3 and APOE4 strata (n=51) including BIN1, MS4A4A, MS4A6A, PICALM and SLC24A4 AD genes and a good number of ribosomal and electron transport mitochondrial proteins (ATP5I, ATP5O, ATP6V1E1, COX17, MRPL27, MRPL33, MRPL35, MRPS17, MRPS21, UQCRH). APOE2 and APOE3 shared eleven genes (ACADM, AK2, ENSA, GPR132, GPR137, HSP90AA1, MCL1, NXF1, TAF1C, UBA7, ZC3H15) whereas the overlap between E2 and E4 was the smallest with eight proteins (KTN1, NDST2, POLR1D, RHTO2, STK17B, TOMM40, TSPAN32, UCHL3). At the pathway level, we observed a lower overlap between APOE strata, with only three shared mitochondrial GO categories among the three haplotypes, and little or none overlap between APOE2 and APOE3 or APOE2 and APOE4 (Supplementary Tables 31–33 and Supplementary Figure 8). In contrast, there was considerable overlap between APOE3 and APOE4 which includes mitochondria biology, secretory vesicles and antigen processing and presentation functions.

In cortex, we found 376, 399 and 366 significant genes (FDR<0.05) for the APOE2, APOE3 and APOE4 strata respectively. Seven common AD candidate genes (APOC1, APOC2, CD44, CDC42, CLPTM1, Dst, PGM2L1) were significant in all three strata; of them, APOC1 and CLPTM1 were also associated in the three strata in blood. In this analysis, the shortest list of APOE-specific genes was found in the APOE4 stratum, which showed the largest overlap with the APOE3 stratum; among the 45 significant genes shared by these strata, we identified several AD genes, including BIN1, MS4A4A, MS4A6A, PICALM and RIN3 in accordance with blood results. The CR1 gene is included among the 19 top genes from the APOE2 and APOE3 strata (ATP1F1, CACNB2, CDC27, CFLAR, COX15, CR1, DCLK1, GOSR2, KANSL1, KLF12, MAPT, MCL1, NSF, POBK, RUFY3, SCDS, SORBS1, SPEN, TTN), whereas APOE, TOMM40, SLC24A4 or WWOX were included among common genes for the APOE2 and APOE4 strata (21 genes: AHNAK, APOE, ARNT, CRTAP, Fbxl16, GART, KALRN, KAT6A, MTMR11, OPA1, PDLIMS, PPFLAI, PURA, RBMS2, SLC24A4, SNGAP1, TOMM40, TSPAN14, UBE2F, WWOX, ZNF264). Enrichment analysis also identified both common and exclusive pathways. Common pathways for AD irrespective of the APOE haplotype were related to adhesion, neuronal development, differentiation, and lipoprotein metabolism; diverse signals related to neuronal death are also present in all three strata. Again, we observed larger overlap between APOE3 and APOE4 pathways (glial cell differentiation and activation, immunological, lipid metabolism, cardiovascular system development and heart function) than for APOE2 and APOE3 (which includes axonogenesis) or APOE2 and APOE4 (mainly phospholipid and lipoprotein metabolism due to APOE, APOC1 and APOC2 genes). (Supplementary Tables 34–36 and Supplementary Figure 9). We observed that APOE2 exclusive pathways include chromatin regulation and telomere maintenance related processes. The APOE3 strata showed the largest number of significant enrichments, but most of them showed a similar annotation in APOE2, or, more frequently, in APOE4 strata, with the exception of antigen processing and presentation, IFNG signalling, astrocyte development and activation and myelin sheath. In APOE4 macrophage activation, fructose metabolism, vitamin D mediated inflammation, inositol phosphate metabolism and cholesterol efflux were the most relevant pathways. Clathrin vesicles, amyloid biology, inflammatory and immune response and glial cell development and differentiation appear as the most relevant categories shared by APOE3 and APOE4 strata.

To identify relevant candidate blood biomarkers tracking brain changes in AD pathology we compared blood and cortex analyses (Figure 4). We identified 68 genes in common for the APOE4 stratum, including CLU, CD2AP, IL6, MS4A2, SLC25A1 or INNPP4A (Figure 4C). In APOE3, 76 common genes were found, including APP, AQP9, ATPAF, CD209, LILRA5, NDUFB3 or PTK2B (Figure 4D). Finally, in the APOE2 stratum, we identified 84 common genes including several ABC receptors (ABCA9, ABCB1, ABCB4, ABCD4), solute carrier molecules (SLC25A3, SLC25A4, SLC35E1, SLC9A9), TLR9 or IL4I1 (Figure 4B). Overlap between APOE strata-specific pathways from blood and cortex showed 6 common pathways for APOE2 (Figure 4F), half of them related to chromatin regulation, 24 common pathways for APOE3 (secretion, regulation of supramolecular fiber organization, site of polarized growth and leukocyte activation involved in inflammatory response, Figure 4G) and 18 shared pathways for APOE4, including clathrin coated vesicles, amyloid-beta processing, mitochondrial transmembrane transport, macrophage activation and monosaccharides and fructose metabolism (Figure 4H). We followed up genes with concordant profiles in both
Figure 4. Summary of candidate genes (A–D) and pathways (E–H) from APOE2 (B, F), APOE3 (C, G) and APOE4 (D, H) common candidates from Blood and Cortex RRA analyses.
blood and cortex (upregulated or downregulated in AD cases vs controls) and showing opposite profiles in APOE2 and APOE4, which included 34 genes with overrepresentation of the gluconeogenesis and fructose metabolic pathways (FBP1, FBP2, SLCT25A1) (Figure 5A). When compared with average expression in normal brains, FBP1, FBP2, RHOD, JPH2, ERAp2 and SLCT1 were upregulated in APOE4 cases when they are usually expressed at low levels, whereas, SNX3 and SUB1, were downregulated in APOE4 cases when they are expressed at very high levels in the normal brain according to GTEx (Figure 5B).

Validation on proteomic datasets

We aimed at investigating if any of our candidate genes were detected and differentially expressed at the proteomic level using blood proteomics data from the ADDN study (931 proteins) and cortex proteomics from four independent datasets (BANNER, BLSA, MAYO and MSBB, 2,658 proteins).

Out of 737 RRA blood candidates, only 38 were present in the ADDN blood proteomic data (Supplementary Table 37 and Supplementary Figure 10). Among them, DE analyses between cases with controls, either overall or stratified by APOE haplotype, identified 8 differentially expressed genes in the unstratified analysis, 8 genes in the APOE4 stratum and 9 in the APOE3 stratum. We could confirm APOE allele-specific effects identified in the RRA analysis for the immune related proteins AIF1, METAP2, NCK1, PRDX1, PRKCZ, RPS27A in the APOE3 stratum, and FCGR2B and SEZ6L2 (involved in SNC development) in the APOE4 stratum. Overall, among these 38 RRA candidates, we identified a cluster of 11 overexpressed proteins in AD cases when compared to controls in the APOE3 stratum, but downregulated APOE4 AD cases including AIF1, APP, GDI2, HSP90AA1, METAP2, NACA, NCK1, PRDX1, RPS27A, SFTPD and UFC1 (Supplementary Figure 11); immunological functions associated to these proteins include leukocyte activation (APP, PRDX1, GDI2), Toll-like receptors (TLRs) cascade (APP, RPS27A, SFTPD) or phagocytosis (NCK1, HSP90AA1, SFTPD, AIF1) in line with our RRA findings.

In cortex, 234 out of 1,039 RRA candidates were present in the proteomics DE meta-analysis, 100 of them showing evidences of association (p<0.05) in at least one stratum or in the unstratified analysis (Supplementary Table 38 and Supplementary Figure 12). Of note, the largest differences between cases and controls were observed among APOE4 carriers, confirming at the proteomic level the role of APOE4.
RRA candidates involved in neurogenesis (DPYSL4, EHD1, GABBR3, MAPK8, UNC13A), or more specifically, in glial cell differentiation (CLU, GAP43, GFAP, GSN). Among APOE3 candidates, we confirmed candidates involved in neurotransmission such as RPH3A PTK2B, ALDH5A1, GABRA2 and APP (the later upregulated in all strata) and genes from the electron transport chain (ALDH5A1, NDUF4, NDUFV3). Confirmed APOE2 candidates included the choline transporter SLCA4A1, involved in myelin production, and the myelin basic protein MBP; MAPT was upregulated in all strata but particularly in the APOE2 stratum. We also confirmed the role of CDC42 and DST in all the strata, but we did not observe association of CD44 and PGM2L1 with AD in this analysis.

**Cell-type-specific expression profiles: cortex snRNAseq**

Since the enrichment analysis showed an over-representation of neuronal development related pathways in all strata, and of cells from the glial lineage in the APOE3 and APOE4 strata, we investigated which cerebral cell types our cortex RRA candidates were mainly expressed in, and which cell types showed largest differences between cases and controls using snRNAseq from the ROSMAP study (Figure 6). We dropped pericytes and endothelial cells from the differential expression analysis because of the low number of cells (~100 cells, <0.3%).

APOE gene was mainly expressed in astrocytes and microglia (Figure 6). According to previous results, APOE is upregulated in microglia from AD subjects when compared with controls (overall and stratified by APOE genotypes). By contrast, in astrocytes we found higher APOE expression levels in cases than controls in the APOE3 stratum (logFC=0.34, p=1.56x10^{-4}), but significant lower expression in APOE4 cases than in controls (logFC=-0.14, p=1.83x10^{-2}, \text{p}_{\text{interaction}}<10^{-5}).

As reported in the original article [19], most neuronal genes were strongly differently expressed in AD cases versus controls. Furthermore, our analysis found this result was consistent irrespective of the APOE haplotype. Given that glial specific signals arose from APOE3 and APOE4 strata, we therefore primarily focused on RRA cortex candidates showing evidence of association with AD in any glial cell type (astrocytes, microglia, oligodendrocytes and oligodendrocyte precursors) within the same APOE stratum (Figure 6 and Supplementary Table 39 and Supplementary Figures 13–16). In fact, RRA candidates were mainly expressed in the glial lineage, showing a linear decrease in expression from APOE2 to APOE4 in the astrocyte and microglia populations, and an increase in expression in the oligodendrocyte subpopulation (Figure 6). The seven genes in common in all the RRA analyses, were downregulated in all cell types except for APOE and APOC1 in microglia, and CD44 in astrocytes (Figure 6). In the stratified analysis, these 7 genes were predominantly downregulated in AD APOE3 carriers and upregulated among APOE4 AD cases when compared to controls, particularly APOC1, DST and CD44 (Supplementary Figure 9). By stratum, APOE2 RRA cortex candidates were mostly upregulated in all cell types (Supplementary Figure 10), and in particular FXR1 and DYNLRB1, the latter only downregulated in microglia. APOE3 RRA candidates showed the largest differences between cases and controls in microglia cells, where APOC1, ALDOA, RPLP0 and DYNLRB1 were strongly upregulated whereas ARL17B was downregulated in AD cases (Supplementary Figure 11). Almost all APOE4 candidate genes were downregulated in both excitatory and inhibitory neurons and upregulated in the glial lineage, particularly TMEM163 and CPM in microglia and GFAP, PLCE1, CLU, CALN1, DgL2 and PDE5A in astrocytes (Supplementary Figure 12); we also observed a strong downregulation of the Serine/Threonine Kinase 17b (STK17B), involved in apoptosis and autophagy, in microglial cells of APOE4 cases.

**DISCUSSION**

The ADAPTED consortium has performed a holistic approach analyzing and integrating diverse data sets from different OMICS technologies, including genomics, transcriptomics (bulk tissue and single cell) and proteomics collected from public repositories and other consortia, resulting in nearly sixty thousand samples analyzed. The novelty of our strategy relies on the use of a stratified approach for the three major APOE haplotypes, and the integration of these signals with a ranked-based algorithm which accommodates different kind of data, resulting in replicated signals at different levels. These signals have been further explored at the single-cell level, pointing to key cellular types for AD. Previous attempts for integrating different OMICS in AD were mainly focused on the identification of quantitative trait loci (QTLs) for mRNA levels, protein levels or epigenomic signatures by means of association analyses [20–23], in some cases stratified by APOE allele [24]. Other approaches involved the independent analysis of the different OMICS and selection of concordant genes [25] or the combination of human GWAS data with mouse transcriptomics [26]. Potential limitations of our study include reduced sample size in some of the datasets, especially for the APOE2 stratum, and the use of unsigned methods (i.e. irrespective of the directionality.
Figure 6. Cortex snRNAseq data from the ROSMAP study. (A) Cell clustering labelled by reported cell type; (B) APOE expression across cell types; (C) violin plot for APOE expression by cell type; (D) UMAP plot for average expression of cortex RRA APOE2 candidates by total gene expression; (E) UMAP plot for average expression of cortex RRA APOE3 candidates by total gene expression; (F) UMAP plot for average expression of cortex RRA APOE4 candidates by total gene expression; (G) UMAP plot for average expression of blood/cortex biomarkers by total gene expression; (H) expression by cell type of the seven genes in common in all the RRA analyses; (I) APOE expression by cell type and case status.
of the expression profiles) for selecting candidate genes in expression datasets.

At the genome level, we were able to detect genome-wide significant signals for ABCA7, BIN1 and PICALM in the APOE3 stratum and for APOE, BIN1, CLU and PICALM in the APOE4 stratum. We identified a novel candidate region for APOE4 carriers on 4p15.1 (33.6Mb-34.3Mb), which, according to the GWAS catalogue (https://www.ebi.ac.uk/gwas/) has not been previously associated with AD, but with schizophrenia, total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes, and PCSK9 levels, a protease that binds to lipoprotein receptors promoting their degradation; a homozygous deletion overlapping this region has been described for the offspring of a consanguineous marriage between first cousins, with cognitive impairment and autistic-like behavior [27]. Sex-stratified analysis identified genome wide significant signals for APOE and BIN1 only in females; this result is in agreement with the recent report from Fan et al., who described a genome-wide significant association for BIN1 only in females [28]. Further stratification of male and female populations by APOE haplotype identified a genome-wide significant intergenic region on 13q31.3 among APOE3 males. This region has been associated with TREM2 levels, circulating Interleukin-1-receptor antagonist levels and triglyceride change in response to fenofibrate in statin-treated type 2 diabetes. This region harbors a USP7 pseudogene (RP11-46444.1) associated with herpesvirus. Interestingly, a potential role of herpes simplex virus infection in AD has recently been object of intense debate [29]. Despite the number of GWAS datasets collected, our study is still underpowered for detecting genuine APOE strata-specific signals with low effect sizes, but resulting gene-level statistics were instrumental to select those DE signals that better correlate with the disease at genetic level. This helps maximize high probable loci involved in the fundamental pathways involved in disease pathogenesis.

The genome-wide expression analysis was performed at two levels: blood and brain cortex. In blood, mitochondrial ribosomal genes and as well as those encoding proteins of the respiratory chain appeared downregulated in cases irrespectively of the APOE haplotype, but more pronounced among APOE4 carriers. Mitochondria are crucial players of energy metabolism but are also the main source of Reactive Oxygen Species (ROS). Mitochondrial dysfunction has been proposed as the primary process triggering all the cascade of events that lead to sporadic late-onset AD. Although this hypothesis has not been confirmed, diverse mitochondrial functions were observed altered in AD and even MCI subjects, showing a significant increase of oxidative stress markers, such as lipid peroxidation and protein oxidation products [30–32]. We did not observe mitochondrial signatures at the whole cortex level, mostly enriched in activated genes from neuronal, apoptosis, vesicle mediated transport and adhesion related pathways, maybe because mitochondrial dysfunction has been reported to be limited to certain hippocampal and temporal cortex neurons [33, 34]. Integration of genome data with expression data at blood and cortex levels through the RRA algorithm, showed a larger overlap of genes and functions in APOE3 and APOE4 carriers than in APOE2 carriers, which appears as a more distinct entity. In fact, we identified signatures for chromatin remodeling and regulation in this stratum at both brain and plasma levels, not observed in the other two strata. Common features of the disease to all three strata are related to lipid metabolism due to APOE (except for the APOE3 carriers), APOC1 and APOC2. A recent report has suggested that APOC1 gene, located in the APOE locus, is an independent risk factor for AD, and that genetic variability in the region is associated with chromatin regulation [35].

AD cases in APOE3 and APOE4 share signaling pathways and functional categories previously reported by other groups such as amyloid-beta formation (APOE, BIN1, CLU, PICALM) mitochondrial physiology (including ATP5H, NDUFS3, MRPI proteins, SNCA, SOD1, SSBP1, SUCLG1 or UQCRH), vesicle mediated transport (including APOC1, APP, BIN1, CIQTNF5, CASS4, CDC42, LDLR, MAPT, PICALM or PTK2B), actin organization (ACTN1, ACTR2, AIF1, ANTXR1, CALD1, CAPZ1, CD2AP, DST, ITGB5, MACF1, MAPT, PALLD, RHOC …) or immunological functions (CCL5, CD209, CD44, CR1, IL6, LILRA3 or MS4A2 among others), but with specific gene signature (for example IL6 in the APOE4 stratum or CD209 in the APOE3 stratum). IL6 plays a critical role in inflammation as well as in neuroprotection through two different mechanisms. Anti-inflammatory effects are mediated by the classical signaling pathways, which involves the binding of IL6 to the membrane bound IL6 receptor (IL6R), whereas proinflammatory effects are mediated by soluble IL6R forms. Classical signaling occurs in microglia whereas trans-signaling is predominant in most neuronal types, astrocytes and oligodendrocytes [36]. Cross-talk between TREM2, CD33 and IL6 (among other ILs) regulating phagocytic capacity, a hallmark of AD among APOE4 carriers according to our results, has been reported in microglia cells [37]. Interestingly, IL6 is degraded by SORL1, encoded by another well-
known AD gene [38]. CD209 is mainly expressed on the surface of dendritic cells, specialized antigen-presenting cells, where regulates DC adhesion, migration and triggering of immune response [39]. In conclusion, our results suggest that APOE-allele specific immunological checkpoints may exist in AD.

Although we have identified signatures of the nervous system development in all strata, they represent a largest proportion of relevant pathways in the APOE3 stratum. In this stratum, enrichment analysis of RRA cortex candidates showed an over-representation of genes involved in cardiac development and function (DLG1, JPH2 or MEF2C among others), supporting a cardiovascular etiology of dementia in this stratum. In line with this finding, we have recently reported a link between cardiac function and AD, that is mediated, at least in part, by CFLAR and caspase dependent mechanisms [40]. In fact, CFLAR and CASP8 are both RRA cortex candidates in this stratum. Another example of the nervous-cardiac connection is GFAP, which participates in the control of heart rate and vascular resistance through the sympathetic nervous system (SNS), which controls heart rate and vascular resistance. We have observed an upregulation of GFAP protein in cortex of all AD cases irrespective of the APOE carrier status. Macrophage activation and Fc gamma receptor mediated phagocytosis appeared as the most exclusive pathways in the APOE4 stratum. Phagocytosis (i.e. the engulfment and digestion of cellular debris) is critical for the degradation of infectious agents and senescent cells, playing a key role in tissue remodeling, immune response, and inflammation. Several Fc receptors (FcRs, FCGR2B, FCRLA and FCRLB) and downstream effectors receptor such as CDC42, RHOD, RHQ and RHT2, GTPases that regulate actin cytoskeleton, have been identified as APOE4 RRA candidates. While FcRs are constitutively active for phagocytosis, the complement receptor (CR)-mediated phagocytosis is activated in presence of additional stimuli. An additional difference between FeR- and CR-mediated phagocytosis is that he former have a higher capacity for triggering the release of inflammatory mediators [41]. In fact, an enhanced release of inflammatory molecules such as IL-6, an APOE4 RRA candidate, IL1β or TNFα has been observed in blood among APOE4 carriers [42, 43] and in blood and brain humanized APOE4 mice models [44–46] has been observed. In this study, we found that CR-related mechanisms were more relevant in APOE2 and APOE3 carriers, with CR1 and ATP5F1 as RRA candidates in both strata.

Macrophages are also involved in the development of atherosclerotic plaques through the intracellular accumulation of lipids and the formation of foam cells, a process counterbalanced by cholesterol efflux, a mechanism identified as an APOE4 specific feature in our study. A key protein in this process seems to be AIF1, a pro-inflammatory molecule expressed primarily in the monocyte/macrophage lineage, which was shown to be downregulated in APOE4 cases and upregulated in plasma samples of APOE3 cases in this study. AIF1 was originally cloned from a rat heart allograft under chronic rejection, and it is involved in several inflammatory conditions including atherosclerosis. Crossbreeding experiments AIF1 and APOE transgenic mice have shown an interaction between these genes leading to atherosclerotic vasculopathy though modulation of the incorporation of degenerated LDL by macrophages [47, 48].

In brain, the resident macrophages, microglia cells, are the specialized phagocytic cells acting through a complement dependent mechanism coupled to ATP production. The analysis of single cell cortex data points to a pivotal role of the glial lineage in the development of AD in accordance with RRA results and current knowledge. Beyond astrocytes and microglia, the main cell types in which APOE is expressed, oligodendrocytes and oligodendrocyte precursors (OPCs) also play a role; interestingly, it has been suggested that astrocytes and oligodendrocytes could also participate in phagocytosis in the brain [49]. But the main role of oligodendrocytes is the production of myelin in the central nervous system, a cholesterol dependent mechanism; oligodendrocytes are continuously generated in the healthy adult brain, being the formation of new myelinating oligodendrocytes during adult life an important mechanism for neuroplasticity [50]. Astrocytes were shown to facilitate all steps of myelination, promoting OPC proliferation through PDGF and FGF2, or inhibiting the differentiation of OPCs into myelin-forming cells through the CD44 receptor. Furthermore, CD44 is a top candidate from cortex RRA analysis upregulated in astrocytic cells of AD cases of all APOE strata, particularly in APOE4, while downregulated in the other cell types including OPCs, illustrating the complexity of AD related mechanism at the cellular level. Myeloid basic protein encoding gene (MBP) is one of the top RRA candidates from the APOE2 stratum, also reinforcing the relevance of myelination in AD in agreement with recent research in the field [51, 52]. In fact, evidence from multiple sclerosis- lesions suggests that Fc receptors and complement have relevant roles in myelin phagocytosis, while in-vitro blockade of Fc or CRs reduced myelin phagocytosis [53].

In summary, through the integration of multi-OMICS datasets we have identified both common and APOE
specific signatures of AD. The ADAPTED consortium has generated isogenic hiPSC derived macrophages, neurons, astrocytes, and microglia carrying the different APOE haplotypes to further explore presented findings in human samples, in a cell-type specific manner. This will support the further elucidation of APOE dependent pathways that drive the AD risk and potentially support developing a therapy for AD patients.

MATERIALS AND METHODS

Table 2 summarizes the datasets and number of individuals by APOE stratum included at each analysis stage (total number of processed samples: 50,737). A flow chart of the analyses performed in this report is shown in Figure 7. Additional information about study datasets is provided as Supplementary Note.

GWAS data

**Study cohorts**

Stage I GWAS meta-analysis comprised 13,305 subjects from nine datasets, including the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the AddNeuroMed study, the Alzheimer’s Disease Genetics Consortium (ADGC), the Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer’s Disease (GenADA), the Mayo Clinic Alzheimer’s Disease Genetic Study, the Neocodex-Murcia study, the National Institute on Aging (NIA) - Late Onset Alzheimer's Disease Family Study, the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP) study and the TGEN study. Stage II meta-analysis (N=14,536 individuals) included the Genome Research at Fundació ACE (GR@ACE) study stage I and the Genetic and Environmental Risk in Alzheimer’s Disease (GERAD) study. The Cohorts for Heart and Ageing Research in Genomic Epidemiology (CHARGE) consortium contributed the Atherosclerosis Risk in Communities (ARIC) study, Cardiovascular Heart Study (CHS), the Framingham study (FS) and the Rotterdam study (RS) for Stage I GWAS meta-analysis (N=11,345 subjects). Additional validation (stage IV) of stage I-III meta-analysis was performed on the European Alzheimer’s Disease Initiative (EADI) dataset (N=8,576 samples). Estimated power for the stage I+II+III meta-analysis was 65.9%, 99.9% and 99.8% for a SNP with MAF=0.2 and OR=1.2 in the E2, E3 and E4 strata respectively, dropping to 28.3%,86.5% and 76.4% for a variant showing MAF=0.2 and OR=1.1.

Whenever possible, clinical information was reviewed to exclude: i) cases not classified as confirmed or probable AD ii) controls with amyloid pathology or history of altered cognition tests.

**Quality control (QC) and imputation**

A standard QC was applied to all datasets, including removal of individuals with more than 3% missing genotypes, with excess autosomal heterozygosity (>0.35 or more than 3 standard deviations (SD) from population mean), those showing a discrepancy between genotypic and reported sex, as well as individuals of non-European ancestry based on SMARTPCA principal component (PC) analyses (exclusion of subjects more than 6 SDs away from the population mean) [54]. Duplicated and related individuals were identified and removed by means of IBS estimates (IBS>0.1875) both within and across studies. At the genotype level, we removed SNPs with missing genotype rate > 5%, not in Hardy-Weinberg equilibrium (HWE) (p<10^-6 in controls) and SNPs with minor allele frequency (MAF) < 1%. When necessary, datasets were updated to genome build GRCh37/hg19.

Genotype imputation was performed at the University of Michigan server using the minimac3 algorithm and the SHAPEIT tool for haplotype phasing with the Haplotype Reference Consortium (HRC) cohort as reference panel [55]. After imputation, only SNPs with an R^2 quality estimate higher than 0.3 and MAF >1% were kept for association analysis.

**APOE stratified association analysis**

Association analysis was performed within each dataset in three independent groups: ε2 stratum (including subjects with APOE genotypes ε2/ε2 and ε2/ε3), ε3 stratum (ε3/ε3 individuals) and ε4 stratum (ε3/ε4 and ε4/ε4 carriers). The ε2/ε4 genotype was excluded because of the combination of both the protective and deleterious alleles. Association of genotype dosages with the AD case-control status was explored through regression models adjusted by age, sex and the first four PC vectors as covariates using PLINK software [56].

**Sex and APOE stratified association analysis**

We also explored the effect of both APOE and sex on susceptibility to AD using two approaches. We first performed a sex stratified analysis using logistic regression models adjusted by age, the first four PC vectors and APOE genotype as a quantitative trait, assigning each allele E2 a value of -1, each E3 allele a value of 0 and each E4 allele a value of +1 (full range: from -2 to 2). Additionally, we performed an association analysis stratified by both APOE and sex. For these analyses, eight datasets from Stage I (ADDN, ADGC, ADNI, GNADA, MAYO, NIA, NXC, ROSMAP, N=12,158 individuals) and Stage II (GR@ACE, 5,741 subjects) were used.

**Meta-analysis (meta-GWAS)**

Within each stage and stratum, association results were combined by meta-analysis using the inverse variance
Table 2. Study datasets.

| GWAS Stage I | ApoE2 Controls | ApoE2 Cases | ApoE3 Controls | ApoE3 Cases | ApoE4 Controls | ApoE4 Cases |
|--------------|----------------|-------------|----------------|-------------|----------------|-------------|
| ADGC         | 191            | 113         | 810            | 1070        | 329            | 2063        |
| ADDN         | 22             | 10          | 126            | 104         | 50             | 140         |
| ADNI         | 40             | 10          | 161            | 153         | 67             | 303         |
| GNADA        | 92             | 35          | 487            | 252         | 164            | 467         |
| NCX          | 78             | 21          | 510            | 150         | 128            | 150         |
| MAYO         | 147            | 24          | 657            | 233         | 286            | 478         |
| NIA          | 68             | 9           | 353            | 94          | 374            | 297         |
| ROSMAP       | 51             | 62          | 153            | 353         | 23             | 200         |
| TGEN         | 71             | 25          | 281            | 261         | 89             | 420         |
| Total Stage I | 760          | 309         | 3538           | 2670        | 1510           | 4518        |
| GWAS Stage II|               |             |                |             |                |             |
| FACE         | 330            | 123         | 2220           | 1314        | 639            | 1115        |
| GERAD        | 780            | 145         | 3572           | 1090        | 1574           | 1634        |
| Total Stage II | 1110        | 268         | 5792           | 2404        | 2213           | 2749        |
| GWAS Stage III|              |             |                |             |                |             |
| ARIC         | 1001           | 144         | 4479           | 688         | 1666           | 567         |
| CHS          | 243            | 44          | 1058           | 240         | 302            | 133         |
| FHS          | 474            | 27          | 2346           | 180         | 687            | 88          |
| RS           | 667            | 102         | 2770           | 548         | 1001           | 435         |
| Total Stage III| 2385        | 317         | 10653          | 1656        | 3656           | 1223        |
| GWAS Stage IV|               |             |                |             |                |             |
| EADI         | 819            | 124         | 4317           | 993         | 1188           | 1135        |
| Total Stage IV | 819         | 124         | 4317           | 993         | 1188           | 1135        |
| TOTAL GWAS   | 5074           | 1018        | 24300          | 7723        | 8567           | 9625        |
| Blood GWES   |               |             |                |             |                |             |
| ADDN         | 14             | 11          | 92             | 79          | 37             | 107         |
| ADNI         | 27             | 3           | 118            | 71          | 48             | 127         |
| Total Blood GWES | 41        | 14          | 210            | 150         | 85             | 234         |
| Cortex GWES  |               |             |                |             |                |             |
| MAYO (TCX)   | 27             | 5           | 112            | 71          | 43             | 118         |
| ROSMAP (DLPFC) | 28        | 26          | 85             | 147         | 13             | 92          |
| MSBB FP      | 2              | 1           | 10             | 16          | 3              | 18          |
| MSBB OVC     | 1              | 3           | 8              | 16          | 4              | 7           |
| MSBB DLPF    | 2              | 0           | 9              | 12          | 5              | 16          |
| MSBB PCG     | 0              | 3           | 5              | 14          | 0              | 14          |
| MSBB PFC     | 1              | 1           | 9              | 15          | 1              | 17          |
| GSE15222     | 26             | 3           | 114            | 48          | 37             | 108         |
| GSE48350 SFG | 9              | 1           | 23             | 8           | 16             | 10          |
| GSE48350 EC  | 8              | 1           | 16             | 5           | 15             | 8           |
| GSE48350 PG  | 10             | 1           | 21             | 8           | 13             | 14          |
| Total Cortex GWES | 114      | 45          | 412            | 360         | 150            | 422         |
| Blood Proteomics |             |             |                |             |                |             |
| ADDN         | 12             | 10          | 46             | 76          | 28             | 110         |
| Total Blood Proteomics | 12    | 10          | 46             | 76          | 28             | 110         |
| Brain proteomics |             |             |                |             |                |             |
| BANNER       | 6              | 6           | 29             | 35          | 6              | 57          |
| BLSA         | 5              | 3           | 7              | 10          | 1              | 7           |
method implemented in METAL [57] or PLINK software programs. SNPs with MAF >1% that were available in at least 60% of the datasets at each stage were included in the meta-analysis. Genomic inflation lambda ($\lambda$) was calculated using the GenABEL package [58]. Manhattans and QQ plots were generated with the qqman R package [59].

**Gene-level analysis**

Gene level analysis was performed using MAGMA software, which compute gene-wise statistics taking into account physical distance and linkage disequilibrium (LD) between markers [60]. All SNPs with MAF above 5% were used in these analyses, setting a distance threshold of 50kb. At each stratum, genes were ranked according to the global p mean value.

**Genome-wide expression analysis (GWES) and meta-analysis**

**Study cohorts**

Whole blood expression profiles for meta-analysis were obtained from ADNI and AddNeuroMed studies

---

**Figure 7. Integrative analysis workflow.**
The cortex gene-expression meta-analysis included Mount Sinai Brain Bank (MSBB) dataset (frontal pole, occipital visual cortex, dorsolateral prefrontal cortex, precentral gyrus, prefrontal cortex), ROSMAP (dorsolateral prefrontal cortex) and MAYO (temporal cortex) studies and GSE15222 [61] and GSE48350 [62] (entorhinal cortex, superior frontal cortex, post-central gyrus) datasets from the GEO repository (N=1,503).

**QC**

For these analyses, we used background corrected and normalized intensity values from expression microarrays distributed by the dataset providers, except for GSE48350. For this GEO dataset, raw. CEL files were downloaded and processed using the Robust Multi-array Average (RMA) algorithm integrated in the affy R package for background correction and normalization [63]. Diagnostic plots included Residuals vs Fitted, Residual vs Leverage, Scale Location, PCA and QQ plots; outlier values identified in these analyses were disregarded. For those datasets provided in different experimental batches, the ComBat function from the sva R package [64] was used to minimize batch effects. A multivariate regression model was fitted to adjust intensity values for covariates, including pH, post-mortem interval (PMI), RNA integrity numbers (RIN), age of death, sex, race and use of lipid lowering medication when available.

**Differential expression analysis**

As for GWAS data, differential expression (DE) analysis between cases and controls was performed independently in the three APOE subgroups using R package limma [65] by dataset and brain region when available. Limma results were adjusted for multiple testing using the Benjamin and Hochberg’s (BH) method. Volcano plots and heatmaps were produced to assess these results. Probes were annotated to gene symbols using appropriate specific libraries, keeping the most differentially expressed mRNA isoform for those genes showing alternative splicing.

**Differential expression meta-analysis (meta-GWES)**

Independent APOE stratified meta-analyses were performed for combining DE results from the different datasets into single ranked gene lists for both blood and cortex. For cortex, only genes present in at least a 70% of the datasets were considered for meta-analysis. Individual logFCs were combined using the Random Effect Model (REM). Given that the analysis included data from different brain regions, genes were ranked according to the Fisher statistics to avoid making assumptions about the directionality of the effect, aimed at identifying candidate markers differentially expressed in the “majority” of studies, where Fisher methods has been described to outperform other methods in terms of power detection, biological association, stability and robustness [66]. All the analyses were performed with the metaDE R tool. Heatmap graphs were generated with the Pheatmap R package.

**Integrative analysis**

In order to obtain per-gene single estimates GWAS and GWES data were combined using the Robust Rank Aggregation (RRA) method [67]. The algorithm, integrated in the RobustRankAggreg R package, uses a probabilistic model for aggregation that is robust to noise and also facilitates the calculation of significance probabilities for all the elements in the final ranking. Two independent runs of the RRA algorithm were performed. In all of them we combined stage I+II+III GWAS meta-analysis plus blood or cortex GWES metaanalyses (Figure 7). Final gene ranks for blood and cortex were generated according to ascending order of the exact p values generated by the RRA algorithm.

**Proteomic data analysis**

Proteomic data from blood (ADDN study) and brain (BANNER, BLSA, MAYO and MSBB studies) were collected. Histograms and boxplots were generated to assess the distribution of normalized intensity protein expression values distributed by data providers. Differential protein expression analyses by study and APOE stratum were performed using limma, with PMI, age, sex and, when available, lipid lowering medication as covariates. Meta-analysis of the diverse brain datasets was performed as described for GWES datasets.

**Single nuclei RNAseq (snRNAseq) data analysis**

Additionally, we explored snRNAseq cortex data from the ROSMAP study [19]. Count matrix provided by ROSMAP study was processed using Seurat package [68]. After QC (filtering out cells that have unique feature counts over 2,500 or less than 200 and cells with >5% mitochondrial counts), data were normalized and scaled. Prior to clustering the cells, we applied the Uniform Manifold Approximation and Projection (UMAP) dimensional reduction technique. Finally, a differential expression analysis between AD cases and controls was performed by each cell type using the edgeR package [69].

**Enrichment analysis**

Enrichment analysis of RRA results was performed using four different tools: WebGestaltR [70, 71], FUMA [72] and gPROFILER [73], for genes passing
the multiple testing correction threshold (p=0.05), and GSEA [74] for full gene ranked lists. The databases being interrogated include GO, KEGG, WikiPathways, and Reactome. Only pathways and GO categories selected by at least two enrichment tools with adjusted p<0.05 and a minimum of three overlapping genes were selected for further exploring.

Data availability statement

Summary statistics are included as Supplementary Tables and will be made available through Synapse repository (https://www.synapse.org/) upon publication.

Most data used in this article are publicly available (see acknowledgement section).

Code availability statement

Code used for this article will be made publicly available through a public Jupyter server (Madrid L, Rubio-Escudero C, Pontes B, González-Pérez A, Riquelme JA, Sáez ME. MOMIC: A Multi-Omics Pipeline for data analysis, integration and interpretation (manuscript in preparation))

AUTHOR CONTRIBUTIONS

Coordination: M.E.S., A.Ruiz; Data Analyses: L.M.M, A.G.P, P.V.M.A., L.K., M.E.S.; CHARGE analysis and coordination: R.X., Q.Y., J.C.B., X.J., S.A., C.V.D., A.D.S, M.F., M.A.I., C.L.S., E.B., S.S.; EADI analysis and coordination: V.D., C.B., B.G.-B., P.A., J.C.L.; GERAD analysis and coordination: A.Ramirez; R.S., J.W.; GR@ACE/DEGESCO analysis and coordination: S.M.G., I.R., P.G.G., A.O., A.Ruiz; Core writing group: A.C.S, L.M.M., M.E.S., A.Ruiz. All other authors contributed data and all authors critically reviewed the paper.

ACKNOWLEDGMENTS

Funding support for the Alzheimer’s Disease Genetics Consortium (ADGC) was provided through the NIA Division of Neuroscience (U01-AG032984). This study was downloaded from NIH dbGaP repository (phs000372.v1).

The AddNeuroMed study is a public-private partnership supported by EFPIA companies and SMEs as part of InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data collection are Iwona Kłoszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilkka Soininen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse), imaging leads are Andy Simmons (London), Lars-Olad Wahlund (Stockholm) and Christian Spenger (Zurich) and bioinformatics leads are Richard Dobson (London) and Stephen Newhouse (London). This dataset was downloaded from Synapse (doi:10.7303/syn2790911).

Data collection and sharing for this project was partially funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Aracron Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and Development, LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Lundomus; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (https://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

The Atherosclerosis Risk in Communities (ARIC) study is carried out as a collaborative study supported by the National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions. Funding support for “Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium” was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). This project was also funded from R01-NS087541.
The Banner Sun Health Research Institute (BANNER) data were provided by Dr. Levey from Emory University. A portion of these data were generated from samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson’s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer’s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson’s Disease Consortium) and the Michael J. Fox Foundation for Parkinson’s Research. This study was downloaded from Synapse (10.7303/syn7170616).

The Baltimore Longitudinal Study on Aging (BLSA) study data were generated from postmortem brain tissue collected through The National Institute on Aging’s Baltimore Longitudinal Study on Aging and provided by Dr. Levey from Emory University. This study was downloaded from Synapse (10.7303/syn3606086).

Infrastructure for the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium is supported in part by the National Heart, Lung, and Blood Institute grant HL105756 and for the neuroCHARGE phenotype working group through the National Institute on Aging grants R01 AG033193, RF1 AG059421, U01 AG049505 and AG052409.

The Cardiovascular Health Study (CHS) research was supported by NHLBI contracts HHSN268201200036C, HHSN26820080007C, HHSN26820180001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC15103, HHSN26820096009C; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, and R01AG033193 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The EADI study has been developed and supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer’s disease) including funding from MEL (Metropole européenne de Lille), ERDF (European Regional Development Fund) and Conseil Régional Nord Pas de Calais. This work was supported by INSERM, the National Foundation for Alzheimer’s disease and related disorders, the Institut Pasteur de Lille and the Centre National de Recherche en Génomique Humaine, CEA, the JPND PERADES, the Laboratory of Excellence GENMED (Medical Genomics) grant no. ANR-10-LABX-0013 managed by the National Research Agency (ANR) part of the Investment for the Future program, and the FP7 AgedBrainSysBio. The Three-City Study was performed as part of collaboration between the Institut National de la Santé et de la Recherche Médicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthélabo. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Aquitaine and Bourgogne Regional Councils, Agence Nationale de la Recherche, ANR supported the COGINUT and COVADIS projects. Fondation de France and the joint French Ministry of Research/INSERM “Cohortes et collections de données biologiques” programme. Lille Génopôle received an unconditional grant from Eisai. The Three-city biological bank was developed and maintained by the laboratory for genomic analysis LAG-BRC - Institut Pasteur de Lille. This work was further supported by the CoSTREAM project (http://www.costream.eu/) and funding from the European Union’s Horizon 2020 research and innovation program under grant agreement 667375. Pascual Sanchez Juan was supported by grants from, IDIVAL, Instituto de Salud Carlos III (Fondo de Investigacion Sanitario, PI08/0139, PI12/02288, PI16/01652, JPND (DEMTTEST PI11/03028) and the CIBERNED program. Belgium samples: Research at the Antwerp site is funded in part by the Belgian Science Policy Office Interuniversity Attraction Poles program, the Belgian Alzheimer Research Foundation, the Flemish government-initiated Flanders Impulse Program on Networks for Dementia Research (VIND) and the Methusalem excellence program, the Research Foundation Flanders (FWO), and the University of Antwerp Research Fund, Belgium. The Antwerp site authors thank the personnel of the VIB Neuromics...
Support Facility, the Biobank of the Institute Born-Bunge and neurology departments at the contributing hospitals. The authors acknowledge the members of the BELNEU consortium for their contributions to the clinical and pathological characterization of Belgium patients and the personnel of the Diagnostic Service Facility for the genetic testing. Finish sample collection: Financial support for this project was provided by Academy of Finland (grant number 307866), Sigrid Jusélius Foundation and the Strategic Neuroscience Funding of the University of Eastern Finland Swedish sample collection: Financially supported in part by the Swedish Brain Power network, the Marianne and Marcus Wallenberg Foundation, the Swedish Research Council (521-2010- 3134, 2015-02926), the King Gustaf V and Queen Victoria’s Foundation of Freemasons, the Regional Agreement on Medical Training and Clinical Research (ALF) between Stockholm County Council and the Karolinska Institutet, the Swedish Brain Foundation and the Swedish Alzheimer Foundation”.

This work has been partly supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195 and No. HHSN268201500001I) and its contract with Affymetrix, Inc. for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. This study was also supported by grants from the National Institute of Aging (R01s AG033040, AG033193, AG054076, AG049607, AG008122, AG016495; and U01-AG049505) and the National Institute of Neurological Disorders and Stroke (R01-NS017950). We would like to thank the dedication of the Framingham Study participants, as well as the Framingham Study team, especially investigators and staff from the Neurology group, for their contributions to data collection. Dr. DeCarli is supported by the Alzheimer’s Disease Center (P30 AG 010129). The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

The genotypic and associated phenotypic data used in the study, Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer's Disease (GenADA) study was contributed by Luis Fornazzari. Memory Clinic, St. Michaels Hospital, Toronto, Serge Gauthier. McGill Centre for Studies in Aging, Alzheimer's Disease Research Unit, Verdun, Quebec, Peter H. St. George-Hyslop. University of Toronto, Center for Research in Neurodegenerative Diseases, Toronto, Ontario, Howard Feldman. Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Anthony Guzman. Clinical Trial Unit, SCO Health Service, Ottawa, Ontario, Michael Borrie. Parkwood Hospital, London, Ontario, Andrew Kertesz. St. Joseph's Hospital, London, Ontario, Richard Delisle. Clinique de Neurologie, Trois-Rivières, Quebec. The study was funded by GlaxoSmithKline, Inc.. Translational Medicine and Genetics, Clinical Imaging Center, R&D Alliances, and Worldwide Epidemiology. The dataset used for analyses described in this manuscript were obtained from NIH dbGaP repository (phs000219.v1.p1).

Data used in the preparation of this article was obtained from the Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) Consortium (Harold et al. 2009). Cardiff University was supported by the Wellcome Trust, Medical Research Council (MRC), Alzheimer’s Research UK (ARUK) and the Welsh Assembly Government. Cambridge University and Kings College London acknowledge support from the MRC. ARUK supported sample collections at the South West Dementia Bank and the Universities of Nottingham, Manchester and Belfast. The Belfast group acknowledges support from the Alzheimer’s Society, Ulster Garden Villages, N.Ireland R&D Office and the Royal College of Physicians/Dunhill Medical Trust. The MRC and Mercer’s Institute for Research on Ageing supported the Trinity College group. The South West Dementia Brain Bank acknowledges support from Bristol Research into Alz oxygen's and Care of the Elderly. The Charles Wolfson Charitable Trust supported the OPTIMA group. Washington University was funded by NIH grants, Barnes Jewish Foundation and the Charles and Joanne Knight Alzheimer's Research Initiative. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Centre and NIHR Queen Square Dementia Biomedical Research Unit. LASER-AD was funded by Lundbeck SA. The Bonn group was supported by the German Federal Ministry of Education and Research (BMBF), Competence Network Dementia and Competence Network Degenerative Dementia, and by the Alfred Krupp von Bohlen und Halbach-Stiftung. The GERAD1 Consortium also used samples ascertained by the NIMH AD Genetics Initiative.

The Genome Research @ Fundació ACE project (GRACE) is supported by Grifols SA, Fundación bancaria ‘La Caixa’, Fundació ACE, and CIBERNED. A.R. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking
The Mayo Clinic Alzheimer’s Disease Genetic Studies, led by Dr. Nilüfer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer’s Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. This dataset was downloaded from Synapse (doi:10.7303/syn5550404).

The Mount Sinai Brain Bank (MSBB) study data were provided by Dr. Levey from Emory University based on postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank provided by Dr. Eric Schadt from Mount Sinai School of Medicine. This dataset was downloaded from Synapse (10.7303/syn3159438).

The Neocodex-Murcia study was funded by the Fundación Alzheimer (Murcia), the Ministerio de Educación y Ciencia (Gobierno de España), Corporación Tecnológica de Andalucía and Agencia IDEA (Consejería de Innovación, Junta de Andalucía). The Diabetes Research Laboratory, Biomedical Research Foundation. University Hospital Clínico San Carlos has been supported by CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); CIBERDEM is an ISCIII Project.

The National Institute on Aging (NIA) - Late Onset Alzheimer's Disease Family Study data were provided by Richard Mayeux, MD, MSc. Columbia University, New York, NY, USA and Tatiana Foroud, PhD. National Cell Repository for Alzheimer's Disease and Indiana University, Indianapolis, IN, USA. This study has received funding from HHSN268200782096C. "NIH contract High throughput genotyping for studying the genetic contributions to human disease”. National Institutes of Health, Bethesda, MD, USA. The study was downloaded from dbGap (phs000168p2v2).

The ROS/MAP study data were provided by the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U10AG46161(TMT proteomics), U10AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at https://www.radc.rush.edu/. This dataset was downloaded from Synapse (doi:10.7303/syn3219045).

The Rotterdam Study (RS) is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) were executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGL)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, and Carolina Medina-Gomez, for their help in creating the GWAS database, and Karol Estrada,
Yurii Aulchenko, and Carolina Medina-Gomez, for the creation and analysis of imputed data. This work has been performed as part of the CoSTREAM project (http://www.costream.eu/) and ORACLE project, and has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667375 and No 678543. HHH A was supported by ZonMW grant number 916.19.151.

The TGEN study was supported by Kronos Life Sciences Laboratories, the National Institute on Aging (Arizona Alzheimer’s Disease Center P30 AG19610, RO1 AG023193, Mayo Clinic Alzheimer’s Disease Center P50 AG16574, and Intramural Research Program), the National Alzheimer’s Coordinating Center (U01 AG016976), and the state of Arizona. TGEN investigators provided free access to genotype data to other researchers via Coriell Biorepositories (http://www.coriell.org).

We thank Dr Beatriz Pontes, Dr Cristina Rubio-Escudero and Dr José C. Riquelme for providing support for the implementation and distribution of analysis code as Jupyter notebooks.

The results published here are in part based on data obtained from the AMP-AD Knowledge Portal (https://adknowledgeportal.synapse.org/).

CONFLICTS OF INTEREST

This study was sponsored by AbbVie Deutschland GmbH & Co. KG. AbbVie contributed to the study design, research, and interpretation of data, writing, reviewing, and approving the abstract. Some authors are currently employed by AbbVie and may own AbbVie stock. Alfredo Cabrera-Socorro is full-time employee of Janssen Pharmaceutical NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

FUNDING

This work has been supported by the ADAPTED consortium, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115975. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations.

REFERENCES

1. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993; 90:1977–81. https://doi.org/10.1073/pnas.90.5.1977 PMID:8446617

2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993; 261:921–23. https://doi.org/10.1126/science.8346443 PMID:8346443

3. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993; 43:1467–72. https://doi.org/10.1212/WNL.43.8.1467 PMID:8350998

4. Havel RJ, Kane JP. Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins. Proc Natl Acad Sci USA. 1973; 70:2015–19. https://doi.org/10.1073/pnas.70.7.2015 PMID:4352966

5. Utermann G, Jaeschke M, Menzel J. Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEMS Lett. 1975; 56:352–55. https://doi.org/10.1016/0014-5793(75)81125-2 PMID:169165

6. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981; 256:9077–83. PMID:7263700

7. Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982; 257:4171–78. PMID:7068630

8. Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ, Goldstein JL, Brown MS, Schonfeld G, Hazzard WR, Blum C. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res. 1982; 23:911–14. PMID:7130859

9. Belloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward. Neuron. 2019; 101:820–38. https://doi.org/10.1016/j.neuron.2019.01.056
10. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–56. PMID:9343467

11. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, et al, and Alzheimer Disease Genetics Consortium (ADGC), and European Alzheimer’s Disease Initiative (EADI), and Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), and Genetic and Environmental Risk in AD/Defining Genetic, and Polygenic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD/PERADES). Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019; 51:414–30. https://doi.org/10.1038/s41588-019-0358-2 PMID:30820047

12. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019; 51:404–13. https://doi.org/10.1038/s41588-018-0311-9 PMID:30617256

13. de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen I, Pedersen NL, Stringa N, Zettergren A, Hernández I, Montreuil L, Antúnez C, Antonell A, et al. Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores. 2020. https://www.medrxiv.org/content/101101/19012021v3 https://doi.org/10.101101/19012021

14. Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer’s disease. Nat Neurosci. 2020; 23:311–22. https://doi.org/10.1038/s41593-020-0599-5 PMID:32112059

15. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, Kunkle BW, Wang LS, Bis JC, Bellenguez C, Harold D, Lunetta KL, DeStefano AL, et al, and IGAP Consortium. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016; 21:108–17. https://doi.org/10.1038/mp.2015.23

16. Ma Y, Jun GR, Zhang X, Chung J, Naj AC, Chen Y, Bellenguez C, Hamilton-Nelson K, Martin ER, Kunkle BW, Bis JC, Debette S, DeStefano AL, et al, and Alzheimer’s Disease Sequencing Project and Alzheimer’s Disease Exome Sequencing–France Project. Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype. JAMA Neurol. 2019; 76:1099–108. https://doi.org/10.1001/jamaneurol.2019.1456 PMID:31180460

17. van der Harst P, van Setten J, Verweij N, Vogler G, Franke L, Maurano MT, Wang X, Mateo Leach I, Eijgelshiem M, Sotoodehnia N, Hayward C, Sorice R, Meirelles O, et al. 52 Genetic Loci Influencing Myocardial Mass. J Am Coll Cardiol. 2016; 68:1435–48. https://doi.org/10.1016/j.jacc.2016.07.729 PMID:27659466

18. Wijssman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghatt B, et al, and NIA-LOAD/NCRAD Family Study Group. Genome-wide association of familial late-onset Alzheimer’s disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011; 7:e1001308. https://doi.org/10.1371/journal.pgen.1001308 PMID:21379329

19. Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurroob F, Jiang X, Martorell AJ, Ransohoff RM, Hafler BP, et al. Author Correction: Single-cell transcriptomic analysis of Alzheimer’s disease. Nature. 2019; 571:E1. https://doi.org/10.1038/s41586-018-1329-6 PMID:31209304

20. Hatcher C, Relton CL, Gaunt TR, Richardson TG. Leveraging brain cortex-derived molecular data to elucidate epigenetic and transcriptomic drivers of complex traits and disease. Transl Psychiatry. 2019; 9:105. https://doi.org/10.1038/s41398-019-0437-2 PMID:30820025

21. Raj T, Li YI, Wong G, Humphrey J, Wang M, Ramdhani S, Wang YC, Ng B, Gupta I, Haroutunian V, Schadt EE, Young-Pearse T, Mostafavi S, et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility. Nat Genet. 2018; 50:1584–92. https://doi.org/10.1038/s41588-018-0238-1 PMID:30297968

22. Traylor M, Adib-Samii P, Harold D, Dichgans M,
23. Bihlmeyer NA, Merrill E, Lambert Y, Srivastava GP, Clark TW, Hyman BT, Das S. Novel methods for integration and visualization of genomics and genetics data in Alzheimer’s disease. Alzheimers Dement. 2019; 15:788–98. https://doi.org/10.1016/j.jalz.2019.01.011 PMID: 30935898

24. Rao S, Ghani M, Guo Z, Deming Y, Wang K, Sims R, Mao C, Yao Y, Cruchaga C, Stephan DA, Rogaeva E. An APOE-independent cis-eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer’s disease risk. Neurobiol Aging. 2018; 66:178.e1–8. https://doi.org/10.1016/j.neurobiolaging.2017.12.027 PMID: 29395286

25. Jiang S, Zhang CY, Tang L, Zhao LX, Chen HZ, Qiu Y. Integrated Genomic Analysis Revealed Associated Genes for Alzheimer’s Disease in APOE4 Non-Carriers. Curr Aler Res. 2019; 16:753–63. https://doi.org/10.2174/1567205016666190823124724 PMID: 31441725

26. Yamaguchi-Kabata Y, Morihara T, Ohara T, Ninomiya T, Takahashi A, Akatsu H, Hashizume Y, Hayashi N, Shigemizu D, Borovicka KA, Ikeda M, Kubo M, Takeda M, Tsunoda T. Integrated analysis of human genetic association study and mouse transcriptome suggests LBH and SHF genes as novel susceptible genes for amyloid-β accumulation in Alzheimer’s disease. Hum Genet. 2018; 137:521–33. https://doi.org/10.1007/s00439-018-1906-z PMID: 30067358

27. Makrythanasis P, Gimelli S, Béna F, Dahoun S, Morris MA, Antonarakis SE, Bottani A. Homozygous deletion of a gene-free region of 4p15 in a child with multiple anomalies: could biallelic loss of conserved, non-coding elements lead to a phenotype? Eur J Med Genet. 2012; 55:63–66. https://doi.org/10.1016/j.ejmg.2011.11.001 PMID: 22080113

28. Fan CC, Banks SJ, Thompson WK, Chen CH, McEvoy LK, Tan CH, Kukull W, Bennett DA, Farrer LA, Mayeux R, Schellenberg GD, Andreassen OA, Desikan R, Dale AM. Sex-dependent autosomal effects on clinical progression of Alzheimer’s disease. Brain. 2020; 143:2272–80. https://doi.org/10.1093/brain/awaa164 PMID: 32591829

29. Balin BJ, Hudson AP. Herpes viruses and Alzheimer’s disease: new evidence in the debate. Lancet Neurol. 2018; 17:839–41. https://doi.org/10.1016/S1474-4422(18)30316-8 PMID: 30264721

30. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol. 2010; 69:155–67. https://doi.org/10.1097/NEU.0b013e3181cb5af4 PMID: 20084018

31. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecacci P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging. 2003; 24:915–19. https://doi.org/10.1016/S0197-4580(03)00031-9 PMID: 12928050

32. Praticò D, Clark CM, Liu F, Rokach J, Lee YY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002; 59:972–76. https://doi.org/10.1001/archneur.59.6.972 PMID: 12056933

33. de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease. Lab Invest. 2000; 80:1323–35. https://doi.org/10.1038/labinvest.3780140 PMID: 10950123

34. Song XN, Zhang LQ, Liu DG, Lin J, Zheng JD, Dai DP, Hei AL, Hayakawa H, Sekiguchi M, Cai JP. Oxidative damage to RNA and expression patterns of MTH1 in the hippocampi of senescence-accelerated SAMP mice and Alzheimer’s disease patients. Neurochem Res. 2011; 36:1558–65. https://doi.org/10.1007/s11064-011-0484-4 PMID: 21538080

35. Zhou X, Chen Y, Mok KY, Kwok TC, Mok VC, Guo Q, Ip FC, Chen Y, Mullapudi N, Giusti-Rodriguez P, Sullivan PF, Hardy J, Fu AK, et al, and Alzheimer’s Disease Neuroimaging Initiative. Non-coding variability at the APOE locus contributes to the Alzheimer’s risk. Nat Commun. 2019; 10:3310. https://doi.org/10.1038/s41467-019-10945-z PMID: 31346172

36. Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016; 1863:1218–27. https://doi.org/10.1016/j.bbamer.2016.03.018 PMID: 27016501
37. Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, Cereghetti G, McGinty D, Anselmo A, Sadreyev RI, Hickman SE, El Khoury J, Colonna M, Tanzi RE. TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer’s Disease. Neuron. 2019; 103:820–35.e7. https://doi.org/10.1016/j.neuron.2019.06.010 PMID:31301936

38. Larsen JV, Petersen CM. SorLA in Interleukin-6 Signaling and Turnover. Mol Cell Biol. 2017; 37:e00641–16. https://doi.org/10.1128/MCB.00641-16 PMID:28265003

39. Zhou T, Chen Y, Hao L, Zhang Y. DC-SIGN and immunoregulation. Cell Mol Immunol. 2006; 3:279–83. PMID:16978536

40. Sáez ME, González-Pérez A, Hernández-Olasagarr B, Beá A, Moreno-Grau S, de Rojas I, Monté-Rubio G, Orellana A, Valero S, Comella JX, Sanchís D, Rúiz A. Genome Wide Meta-Analysis identifies common genetic signatures shared by heart function and Alzheimer’s disease. Sci Rep. 2019; 9:16665. https://doi.org/10.1038/s41598-019-52724-2 PMID:31723151

41. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999; 17:593–623. https://doi.org/10.1146/annurev.immunol.17.1.593 PMID:10358769

42. Fan YY, Cai QL, Gao ZY, Lin X, Huang Q, Tang W, Liu JH. APOE ε4 allele elevates the expressions of inflammatory factors and promotes Alzheimer’s disease progression: A comparative study based on Han and She populations in the Wenzhou area. Brain Res Bull. 2017; 132:39–43. https://doi.org/10.1016/j.brainresbull.2017.04.017 PMID:28461186

43. Gale SC, Gao L, Mikacenic C, Coyle SM, Raafails N, Murray Dudenkov T, Madenspacher JH, Draper DW, Ge W, Aloor JJ, Azzam KM, Lai L, Blackshear PJ, et al. APOE4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol. 2014; 134:127–34. https://doi.org/10.1016/j.jaci.2014.01.032 PMID:24655576

44. Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, LaDu MJ. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia. 2012; 60:559–69. https://doi.org/10.1002/glia.22289 PMID:2228589

45. Vitcek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009; 30:1350–60. https://doi.org/10.1016/j.neurobiolaging.2007.11.014 PMID:18155324

46. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, Warner DS, Laskowitz DT. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem. 2003; 278:48529–33. https://doi.org/10.1074/jbc.M306923200 PMID:14507923

47. Mishima T, Iwabuchi K, Fujii S, Tanaka SY, Ogura H, Watano-Miyata K, Ishimori N, Andoh Y, Nakai Y, Iwabuchi C, Ato M, Kitabatake A, Tsutsumi H, Onoé K. Allograft inflammatory factor-1 augments macrophage phagocytotic activity and accelerates the progression of atherosclerosis in ApoE/- mice. Int J Mol Med. 2008; 21:181–87. PMID:18204784

48. Eganza-Gorroño L, Chinnasamy P, Casimiro I, Almonte VM, Parikh D, Oliveira-Paula GH, Jayakumar S, Law C, Riascos-Bernal DF, Sibinga NE. Allograft inflammatory factor-1 supports macrophage survival and effectorcytosis and limits necrosis in atherosclerotic plaques. Atherosclerosis. 2019; 289:184–94. https://doi.org/10.1016/j.atherosclerosis.2019.07.022 PMID:31439353

49. Watabe K, Osborne D, Kim SU. Phagocytic activity of human adult astrocytes and oligodendrocytes in culture. J Neuropathol Exp Neurol. 1989; 48:499–506. https://doi.org/10.1097/0005072-198909000-00001 PMID:2671269

50. McKenzie IA, Ohayon D, Li H, de Faria JP, Emery B, Tohyama K, Richardson WD. Motor skill learning requires active central myelination. Science. 2014; 346:318–22. https://doi.org/10.1126/science.1254960 PMID:25324381

51. Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018; 6:22. https://doi.org/10.1186/s40478-018-0155-3 PMID:29499767

52. Wang SS, Zhang Z, Zhu TB, Chu SF, He WB, Chen NH. Myelin injury in the central nervous system and Alzheimer’s disease. Brain Res Bull. 2018; 140:162–68. https://doi.org/10.1016/j.brainresbull.2018.05.003 PMID:29730417

53. Galloway DA, Phillips AEM, Owen DRJ, Moore CS. Corrigendum: Phagocytosis in the Brain: Homeostasis and Disease. Front Immunol. 2019; 10:1575.
54. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet. 2006; 2:e190. 
https://doi.org/10.1371/journal.pgen.0020190 PMID: 17194218

55. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, Kang HM, Fuchsberger C, Danecik P, Sharp K, Luo Y, Sidore C, Kwong A, et al, and Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016; 48:1279–83. 
https://doi.org/10.1038/ng.3643 PMID: 27548312

56. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81:559–75. 
https://doi.org/10.1086/519795 PMID: 17701901

57. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010; 26:2190–91. 
https://doi.org/10.1093/bioinformatics/btq340 PMID: 20616382

58. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007; 23:1294–96. 
https://doi.org/10.1093/bioinformatics/btm108 PMID: 17384015

59. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. J Open Source Softw. 2018; 3:731. 
https://doi.org/10.21105/joss.00731

60. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015; 11:e1004219. 
https://doi.org/10.1371/journal.pcbi.1004219 PMID: 25885710

61. Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, McCorquodale DS 3rd, Cuello C, Leung D, et al, and NACC-Neuropathology Group. Genomic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009; 84:445–58. 
https://doi.org/10.1016/j.ajhg.2009.03.011 PMID: 19361613

62. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, Beach T, Miller C, Troncoso J, Trojanowski JQ, Zielke HR, Cotman CW. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci USA. 2008; 105:15605–10. 
https://doi.org/10.1073/pnas.0806883105 PMID: 18832152

63. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy---analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20:307–15. 
https://doi.org/10.1093/bioinformatics/btg405 PMID: 14960456

64. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28:882–83. 
https://doi.org/10.1093/bioinformatics/bts034 PMID: 22257669

65. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47. 
https://doi.org/10.1093/nar/gkv007 PMID: 25605792

66. Chang LC, Lin HM, Sibille E, Tseng GC. Meta-analysis methods for combining multiple expression profiles: comparisons, statistical characterization and an application guideline. BMC Bioinformatics. 2013; 14:368. 
https://doi.org/10.1186/1471-2105-14-368 PMID: 24359104

67. Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012; 28:573–80. 
https://doi.org/10.1093/bioinformatics/btr709 PMID: 22247279

68. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018; 36:411–20. 
https://doi.org/10.1038/nbt.4096 PMID: 29608179

69. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26:139–40. 
https://doi.org/10.1093/bioinformatics/btp616 PMID: 19910308

70. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019; 47:W199–205. 
https://doi.org/10.1093/nar/gkz401 PMID: 31114916

71. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005; 33:W741–48. 
https://doi.org/10.1093/nar/gki475 PMID: 15980575
72. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017; 8:1826. https://doi.org/10.1038/s41467-017-01261-5 PMID:29184056

73. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019; 47:W191–98. https://doi.org/10.1093/nar/gkz369 PMID:31066453

74. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102:15545–50. https://doi.org/10.1073/pnas.0506580102 PMID:16199517
SUPPLEMENTARY MATERIALS

Extended datasets description

The Alzheimer's disease genetics consortium (ADGC)

The National Institute on Aging (NIA) Alzheimer's Disease Centres (ADCs) cohort includes subjects ascertained and evaluated by the clinical and neuropathology cores of the 29 NIA-funded ADCs [1]. Data collection was coordinated by the National Alzheimer's Coordinating Center (NACC). The ADC cohort consists of autopsy-confirmed and clinically-confirmed AD cases, and cognitively normal elders (CNEs) with complete neuropathology data who were older than 60 years at age of death, and living CNEs evaluated using the Uniform dataset (UDS) protocol who were documented to not have mild cognitive impairment (MCI) and were between 60 and 100 years of age at assessment.

The AddNeuroMed study

AddNeuroMed was a public-private partnership for biomarker discovery and replication in Alzheimer’s disease [2, 3]. It was designed as a multi-center study in Europe with the first patient enrolled in January 2006 and the last in February 2008. The study protocol was planned for a baseline assessment visit with follow ups every 3 months for the first year, proceeded by annual visits that continued through 2013. The study enrolled a total of 258 AD, 257 MCI and 266 controls, not all with complete data at each assessment.

The Alzheimer’s disease neuroimaging initiative (ADNI)

Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). The ADNI study has three phases: ADNI1, ADNI GO and ADNI2. For up-to-date information, see http://www.adni-info.org.

The atherosclerosis risk in communities (ARIC)

The ARIC study is a population-based cohort study of atherosclerosis and clinical atherosclerotic diseases (ARIC Investigators 1989) [4]. At its inception (1987-1989), 15,792 men and women, including 11,478 white and 4,266 black participants were recruited from four U.S. communities: Suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi. In the first 3 communities, the sample reflects the demographic composition of the community. In Jackson, only black residents were enrolled. Participants were between age 45 and 64 years at their baseline examination in 1987-1989 when blood was drawn for DNA extraction and participants consented to genetic testing. Vascular risk factors and outcomes, including transient ischemic attack, stroke and dementia, were determined in a standard fashion. During the first 2 years (1993-1994) of the third ARIC examination (V3), participants aged 55 and older from the Forsyth County and Jackson sites were invited to undergo cranial MRI. This subgroup of individuals with MRI scanning represents a random sample of the full cohort because examination dates were allocated at baseline through randomly selected induction cycles.

The Banner Sun Health Research Institute (Banner) study

This study is based on 201 post-mortem brain tissue samples obtained from the Banner Sun Health Research Institute's Brain and Body Donation Program. The tissue set came from 101 cognitively normal (controls) and 100 Alzheimer’s disease (AD) cases. Label free proteome analysis was done on the dorsolateral prefrontal cortex from all individuals. Post-mortem neuropathological evaluation was performed at Banner Sun Health Research Institute. This included amyloid plaque distribution according to CERAD criteria and neurofibrillary tangle pathology assessed with Braak staging. Control cases were defined as cognitively normal within on average 9 months of death with low CERAD (0.13 ±0.35) and Braak (2.26 ±0.94) measures for amyloid and tau neuropathology, respectively. In contrast, AD cases were demented at the last clinical research assessment, and the brains showed high CERAD (2.9 ±0.31) and Braak (5.4 ±0.82) scores consistent with moderate to severe neuropathological burden. There was no significant difference in age or postmortem interval (PMI) between control and AD.

The Baltimore longitudinal study on aging (BLSA) study

We BLSA study included 97 post-mortem brain tissue samples from the National Institute on Aging’s
Baltimore Longitudinal Study of Aging (BLSA, https://www.blsa.nih.gov/). The tissue set came from 50 individuals representing 15 controls, 15 AsymAD and 20 AD cases. For 47 cases, we analyzed tissue from both the dorsolateral prefrontal cortex (FC, Brodmann Area 9) and precuneus (PC, Brodmann Area 7). Both regions are affected in AD, and PC is a site of early amyloid deposition and glucose hypometabolism. Post-mortem neuropathological evaluation was performed at the Johns Hopkins Alzheimer’s Disease Research Center with the Uniform Data Set including amyloid plaque distribution according to CERAD criteria and neurofibrillary tangle pathology assessed with Braak staging. Control cases were defined as cognitively normal within on average 9 months of death with low CERAD (0.13 ±0.35) and Braak (2.26 ±0.94) measures for amyloid and tau neuropathology, respectively [5]. In contrast, AD cases were demented at the last clinical research assessment, and the brains showed high CERAD (2.9 ±0.31) and Braak (5.4 ±0.82) scores consistent with moderate to severe neuropathological burden. AsymAD cases were cognitively normal proximate to death and had high CERAD (2.1 ±0.52) and moderate Braak (3.6 ±0.99).

The cohort for heart and ageing research in genomic epidemiology (CHARGE) consortium

The CHARGE consortium currently includes six large, prospective, community-based cohort studies that have genome-wide variation data coupled with extensive data on multiple phenotypes [5]. A neurology working-group arrived at a consensus on phenotype harmonization, covariate selection and analytic plans for within-study analyses and meta-analysis of results [6]. Consent procedures, examination and surveillance components, data security, genotyping protocols and study design at each study were approved by a local Institutional Review Board, details are provided below. Of the six studies, we included in this study the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS) and the Rotterdam Study (RS).

The cardiovascular health study (CHS)

The CHS is a population-based cohort study of risk factors for coronary heart disease and stroke in adults ≥ 65 years conducted across four field centers [7]. The original predominantly European ancestry cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare eligibility lists; subsequently, an additional predominantly African-American cohort of 687 persons was enrolled for a total sample of 5,888. Blood samples were drawn from all participants at their baseline examination and DNA was subsequently extracted from available samples. Genotyping was performed at the General Clinical Research Center’s Phenotyping/Genotyping Laboratory at Cedars-Sinai among CHS participants who consented to genetic testing and had DNA. European ancestry participants were excluded from the GWAS study sample due to the presence at study baseline of coronary heart disease, congestive heart failure, peripheral vascular disease, valvular heart disease, stroke or transient ischemic attack or lack of available DNA. Among those with successful GWAS, 567 European ancestry participants had available FreeSurfer measures for this analysis. CHS was approved by institutional review committees at each field center and individuals in the present analysis had available DNA and gave informed consent including consent to use of genetic information for the study of cardiovascular disease.

The European Alzheimer’s disease initiative (EADI) consortium

All the 2,240 Alzheimer’s disease cases were ascertained by neurologists from Bordeaux, Dijon, Lille, Montpellier, Paris, Rouen, and were identified as French NHW ancestry. Clinical diagnosis of probable Alzheimer’s disease was established according to the DSM-III-R and NINCDS-ADRDA criteria. Controls were selected from the 3C Study [8]. This cohort is a population-based, prospective (10-years follow-up) study of the relationship between vascular factors and dementia. It has been carried out in three French cities: Bordeaux (southwest France), Montpellier (southeast France) and Dijon (central eastern France). A sample of non-institutionalized, over-65 subjects was randomly selected from the electoral rolls of each city. Between January 1999 and March 2001, 9,686 subjects meeting the inclusion criteria agreed to participate. Following recruitment, 392 subjects withdrew from the study. Thus, 9,294 subjects were finally included in the study (2,104 in Bordeaux, 4,931 in Dijon and 2,259 in Montpellier). Genomic DNA samples of 7,200 individuals were transferred to the French Centre National de Génotypage (CNG). First stage samples that passed DNA quality control were genotyped with Illumina Human 610-Quad BeadChips. At the end we removed 308 samples because they were found to be first- or second-degree relatives of other study participants or were assessed non-European descent based on genetic analysis using methods described in 89. In this final sample, at 10 years of follow-up, 564 individuals suffered from Alzheimer’s disease with 95 prevalent and 469 incident cases.

The Framingham heart study (FHS)

The FHS is a three-generation, single-site, community-based, ongoing cohort study that was initiated in 1948
to investigate the risk factors for cardiovascular disease. It now comprises 3 generations of participants: the Original cohort followed since 1948; their Offspring and spouses of the Offspring (Gen 2), followed since 1971 [9]; and children from the largest Offspring families enrolled in 2000 (Gen 3) [10]. The Original cohort enrolled 5,209 men and women who comprised two-thirds of the adult population then residing in Framingham, MA. Survivors continue to receive biennial examinations. The Offspring cohort comprises 5,124 persons (including 3,514 biological offspring) who have been examined approximately once every 4 years. The Third-generation includes 4,095 participants with at least one parent in the Offspring Cohort. The first two generations were invited to undergo an initial brain MRI in 1999-2005, and for Gen 3, brain MRI began in 2009. The population of Framingham was virtually entirely white (Europeans of English, Scots, Irish and Italian descent) in 1948 when the Original cohort was recruited. Self-reports of ethnicity across all three generations were 99.7% whites, reflecting the ethnicity of the population of Framingham in 1948. FHS participants had DNA extracted and provided consent for genotypeing, and eligible participants underwent genome-wide genotyping.

Multi-site collaborative study for genotype-phenotype associations in Alzheimer's disease and longitudinal follow-up of genotype-phenotype associations in Alzheimer's disease and neuroimaging component of genotype-phenotype associations in Alzheimer's disease (GenADA)

GenADA was a multi-site collaborative study, involving GlaxoSmithKline Inc and nine medical centers in Canada, including 1000 AD patients and 1000 ethnically-matched controls in order to associate DNA sequence (allelic) variations in candidate genes with AD phenotypes [11, 12]. The study consists of both retrospective and prospective data. Where possible, biological relatives with Alzheimer’s (up to third degree relationship) and unaffected siblings of AD cases were also recruited.

The genetic and environmental risk for Alzheimer’s disease (GERAD1) consortium

The GERAD1 sample comprised up to 3941 AD cases and 7848 controls. A subset of this sample has been used in this study and were genotyped at the Sanger Institute on the Illumina 610-quad chip. These samples were recruited by the Medical Research Council (MRC) Genetic Resource for AD (Cardiff University; Kings College London; Cambridge University; Trinity College Dublin), the Alzheimer’s Research UK (ARUK) Collaboration (University of Nottingham; University of Manchester; University of Southampton; University of Bristol; Queen’s University Belfast; the Oxford Project to Investigate Memory and Ageing (OPTIMA), Oxford University); Washington University, St Louis, United States; MRC PRION Unit, University College London; London and the South East Region AD project (LASER-AD), University College London; Competence Network of Dementia (CND) and Department of Psychiatry, University of Bonn, Germany and the National Institute of Mental Health (NIMH) AD Genetics Initiative. All AD cases met criteria for either probable (NINCDS-ADRDA, DSM-IV) or definite (CERAD) AD. All elderly controls were screened for dementia using the MMSE or ADAS-cog, were determined to be free from dementia at neuropathological examination or had a Braak score of 2.5 or lower.”

The genome research @ fundació ACE project (GR@ACE) study

The GR@ACE study comprises 4,120 AD cases and 3,289 control individuals. Cases were recruited from Fundació ACE, Institut Català de Neurociències Aplicades (Catalonia, Spain). Diagnoses were established by a multidisciplinary working-group, including neurologists, neuropsychologists, and social workers, according to the DSM-IV criteria for dementia and to the National Institute on Aging and Alzheimer’s Association’s (NIA-AA) 2011 guidelines for defining AD [13]. Dementia individuals diagnosed with probable or possible AD at any moment of their clinical course were considered AD cases.

Briefly, participants were genotyped using the Axiom 815K Spanish Biobank Array (Thermo Fisher), performed in the Spanish National Center for Genotyping (CeGEN, Santiago de Compostela, Spain). Individuals were excluded for low-quality samples, (call rate <97%), excess heterozygosity, sample duplicates, or relation to another sample (PIHAT > 0.1875). Individuals were excluded if sex discrepancy was detected. Population outliers of European ancestry were also removed. Variants were excluded if they departed from the Hardy-Weinberg equilibrium (P-value ≤ 1 × 10-6), presented a different missing rate between cases and controls (P-value < 5 × 10-4 for the difference), or had a low frequency (MAF < 0.01) or low call rate < 95%. High-quality variants were imputed in Michigan Server using the Haplotype reference consortium (HRC) panel (https://imputationserver.sph.umich.edu). Only high imputation quality markers (MAF > 0.05 and R2>0.03) were used for downstream analysis. Further information about phenotyping and GWAS quality controls have been previously provided [14].
The Mayo Clinic LOAD Genome-wide Association Study (MAYO)

Subjects from the Mayo LOAD GWAS were selected from two clinical AD Case-Control series: Mayo Clinic Jacksonville (MCJ), Mayo Clinic Rochester (MCR) and a neuropathological series of autopsy-confirmed subjects from the Mayo Clinic Brain Bank [15]. All subjects from the clinical series (MCJ and MCR) were diagnosed by a Mayo Clinic neurologist; all control subjects had a Clinical Dementia Rating score of zero at the most recent time of testing; all LOAD patients had a diagnosis of probable or possible AD according to the NINCDS-ADRDA criteria [16]. All ADs had definite diagnosis according to the NINCDS-ADRDA criteria and had Braak scores of ≥4.0. All non–AD Controls had Braak scores of ≤2.5; many had brain pathology unrelated to AD.

The Mount Sinai Brain Bank (MSBB) Study

Brain specimens were obtained from the Mount Sinai/JJ Peters VA Medical Center Brain Bank (MSBB) which holds over 1,700 samples. This cohort was assembled after applying stringent inclusion/exclusion criteria and represents the full spectrum of disease severity. Neuropathological assessments are performed according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) protocol and include assessment by hematoxylin and eosin, modified Bielschowsky, modified thioflavin S, and anti-β amyloid (4G8), anti-tau (AD2) and anti-ubiquitin (Daka Corp.). Each case is assigned a Braak AD-staging score for progression of neurofibrillary neuropathology. Quantitative data regarding the density of neuritic plaques in the middle frontal gyrus, orbital frontal cortex, superior temporal gyrus, inferior parietal cortex and calcarine cortex are also collected as described. Clinical dementia rating scale (CDR) and mini–mental state examination (MMSE) severity tests are conducted for assessment of dementia and cognitive status. Final diagnoses and CDR scores are conferred by consensus. Based on CDR classification, subjects are grouped as no cognitive deficits (CDR = 0), questionable dementia (CDR = 0.5), mild dementia (CDR = 1.0), moderate dementia (CDR = 2.0), and severe to terminal dementia (CDR = 3.0–5.0). Covariates including demographic and neuropathological data were collected on the samples used for this project including postmortem interval, race, age of death, clinical dementia rating, clinical neuropathology diagnosis, CERAD, Braak, sex, and a series of neuropathological variables.

The Neocodex-Murcia Study (NXC)

The study includes 327 sporadic AD patients and 801 controls with unknown cognitive status from the Spanish general population collected by Neocodex [17, 18]. AD patients were diagnosed as possible or probable AD in accordance with the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) [16].

The National Institute on Aging - Late Onset Alzheimer’s Disease Family Study (NIA)

The goal of this study is to identify and recruit families with two or more siblings with the late-onset form of Alzheimer’s disease and a cohort of unrelated, non-demented controls similar in age and ethnic background, and to make the samples, the clinical and genotyping data and preliminary analyses available to qualified investigators worldwide [19]. Genotyping by the Center for Inherited Disease Research (CIDR) was performed using the Illumina Infinium II assay protocol with hybridization to Illumina Human 610Quadv1_B Beadchips.

The Religious Orders Study and Memory and Aging Project (ROS/MAP) Study

The Religious Orders Study (ROS) is a longitudinal clinical-pathologic cohort study of aging and Alzheimer’s disease (AD) from the Rush University that enrolled individuals from religious communities for longitudinal clinical analysis and brain donation [20]. Participants were enrolled from more than 40 groups of religious orders (nuns, priests, brothers) across the United States. Medical conditions are documented starting in 1994 by clinical evaluation or self-report. Alzheimer’s Disease status was determined by a computer algorithm based on cognitive test performance with a series of discrete clinical judgments made in series by a neuropsychologist and a clinician.

The Memory and Aging Project (MAP) is a longitudinal, epidemiologic clinical-pathologic cohort study of common chronic conditions of aging with an emphasis on decline in cognitive and motor function and risk of Alzheimer’s disease that began in 1997 and is run from Rush University [20]. This study was designed to complement the ROS study by enrolling individuals with a wider range of life experiences and socioeconomic status into a study of similar structure and design as ROS. The study enrolled older individuals without any signs of dementia, primarily recruiting from continuous care retirement communities throughout north-eastern Illinois, USA. Diagnoses of dementia and AD are performed in an identical manner to the ROS study.

www.aging-us.com  9308  AGING
The Rotterdam study

The Rotterdam Study is a prospective, population-based cohort study among individuals living in the well-defined Ommoord district in the city of Rotterdam in the Netherlands [21, 22]. The aim of the study is to determine the occurrence of cardiovascular, neurological, ophthalmic, endocrine, hepatic, respiratory, and psychiatric diseases in elderly people. The cohort was initially defined in 1990 among approximately 7,900 persons, aged 55 years and older, who underwent a home interview and extensive physical examination at the baseline and during follow-up rounds every 3–4 years (RS-I). The cohort was extended in 2000/2001 (RS-II, 3,011 individuals aged 55 years and older) and 2006/2008 (RS-III, 3,932 subjects, aged 45 and older). Written informed consent was obtained from all participants and the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam, approved the study.

The Translational Genomics Research Institute (TGEN) study

The TGEN GWAS study included 643 late onset AD cases and 404 controls from a neuropathological cohort, and 197 late onset AD cases and 114 controls from a clinical cohort [23].

CONSORTIA MEMBERSHIP

ADAPTED consortium

Margot Bakker1, Lamiaa Bahnassawy1, Peter Reinhardt1, Janina Ried1, Eric Mohler1, Heike Hering2, Maria Eugenia Sáez3, Antonio González-Pérez3, Laura Madrid3, Santos Mañes4, Keiryn Bennett5, Cornelia van Duijn6, Shahzad Ahmad6, Agustin Ruiz7, Adela Orellana7, Pablo García8, Itziar de Rojas8, Carlos Vicario8, Eva Díaz-Guerra8, Esther Arribas-González8, Alfredo Cabrera9, Thomas Hankemeier10, Isabelle Kohker10, Remko van Vught10, Carlos Fisac11, Tania Fowke11, Bridget Glashyer12, Michael Peitz13, Alfredo Ramírez13, Pamela Martino Adami13, Carolina Dalmasso13, Pamela Kleineidam13.

1 AbbVie Deutschland GmbH & Co. KG, Genomics Research Center, Knollstrasse, 67061 Ludwigshafen, Germany; 2 Biogen Inc., Cambridge, MA, USA; 3 Andalusion Bioinformatics Research Centre (CAEBi)Sevilla, Spain; 4 Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB/CSIC); 5 DC Biosciences, James Lindsay Place, Dundee, DD1 5JJ, UK; 6 Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands; 7 Research Center and Memory clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain; 8 Instituto Cajal, CSIC, Madrid, Spain; 9 Janssen Research and Development, a Division of Janssen Pharmaceutica N.V., Beerse, Belgium; 10 Analytical Biosciences, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands; 11 MIMETAS BV, JH Oortweg 19, Leiden, CH, 2333 The Netherlands; 12 MODUS Research and Innovation Ltd., Unit D Tayside Software Centre, Gemini Crescent, Dundee Technology Park, Dundee, DD2 1TY, UK; 13 Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany.

Cohorts for heart and aging research in genomic epidemiology consortium (CHARGE) consortium

Maria Vronskaya, Aura Frizatti, Nandini Badarinarayana, Rachel Raybould, Taniesha Morgan, Per Hoffmann, Denise Harold, Amy Gerrish, Nicola Denning, Nick C. Fox, Joseph T. Hughes, Yogen Patel, Makrina Danilidou, James Uphill, Daniela Galiberti, Elio Scarpini, Johannes Kornhuber, Sabrina Sordon, Manuel Mayhaus, Wei Gu, Annette M Hartmann, Simon Lovestone, Rebecca Sussams, Clive Holmes, Wolfgang Maier, Amit Kavalia, Susanne Moebus, James Turton, Jenny Lord, Iwona Kloszewska, Aoibhinn Lynch, Brian Lawlor, Michael Gill, Monica Diez-Fairén, Ignacio Alvarez, Antonio Ciaramella, Chiara Cupidi, Raffaele Giovanni Maletta, Roberta Cecchetti, Magda Tsolaki, David Craig, Despoina Avramidou, Antonia Germanou, Maria Koutroumani, Olympia Gkatzima, Harald Hampel, David C. Rubinszttein, Lutz Fröhlich, Bernadette McGuinness, Janet A. Johnston, Peter Passmore, Jonathan M. Schott, Jason D. Warren, Michelle K. Lupton, Petra Proitsi, John Powell, John S. K. Kauwe, Michelangelo Mancuso, Ulumbo Bonuccelli, Andrew McQuillin, Gill Livingston, Nicholas J. Bass, John Hardy, Jose Bras, Minerva M. Carrasquillo, Rita Guazzetti, William Seed, Elizabeth Fisher, Carlo Masullo, Gina Bisceglio, Li Ma, Neil R. Graff-Radford, Angela Hodges, Martin Scherer, Matthias Riemenschneider, Reinhard Heun, Heike Kölsch, Markus Leber, Isabella Heuser, Ina Giegling, Michael Hüll, John Morris, Kevin Mayo, Thomas Feulner, Dmitriy Drichel, Thomas D. Cushion, Paul Hollingworth, Rachel Marshall, Alun Meggy, Georgina Menzies, Ganna Leonenko, Detelina Grozeva, Giancarlo Russo, Frank Jessen, Bruno Vellas, Emma Vardy, Karl-Heinz Jöckel, Martin Dignams, David Mann, Stuart Pickering-Brown, Norman Klopp, H-Erich Wichmann, Kevin Morgan, Kristelle Brown, Christopher Medway, Markus M. Nöthen, Nigel M. Hooper, Antonio Daniele, Anthony Bayer, John Gallacher, Hendrik van den Bussche, Carol Brayne.
Steffi Riedel-Heller, Ammar Al-Chalabi, Christopher E. Shaw, Jens Wittfang, Victoria Alvarez, Andrew B. Singleton, John Collinge, Simon Mead, Martin Rossor, Natalie S. Ryan, Benedetta Nacmias, Sandro Sorbi, Eleonora Sacchinelli, Gianfranco Spalletta, Carlo Caltagirone, Maria Donata Orfei, Robert Clarke, A. David Smith, Donald Warden, Gordon Wilcock, Amalia Cecilia Bruni, Maura Gallo, Yoav Ben-Shlomo, Patrizia Meccoci, Pau Pastor, Oliver Peters, Virginia Bocardi, Nick Warner, Panagiota Deloukas, Carlos Cruhaga, Rhian Gwilliam, Patrick G. Kehoe, Seth Love, Chris Corcoran, JoAnn Tschanz, Ron Munger, Michael C. O’Donovan, Lesley Jones, Michael J. Owen, Valentina Escott-Price, Alfredo Ramirez, Peter A. Holmans, Julie Williams.

**The European Alzheimer’s disease initiative (EADI) consortium**

Benjamin Grenier-Boley, Vincent Damotte, Anne Boland, Céline Bellenguez, Kristel Sleepers, Robert Olaso, Mikko Hiltunen, Jacques Epelbaum, Jean-Guillaume Garnier, Marie-Laure Moutet, Delphine Bacq, Maria Del Zompo, Ignacio Mateo, Florentino Sanchez-Garcia, Maria Candida Deniz Naranjo, David Wallon, Fabienne Garzia, Bertrand Fin, Stéphane Meslage, Sebastiaan Engelborghs, Rik Vandenberghae, Peter De Deyn, Alessio Squassina, Eloy Rodriguez-Rodriguez, Carmen Munoz-Fernandez, Yolanda Aladro Benito, Hakan Thonberg, Vilmantas Giedraitis, Lena Kilander, RoseMarie Brundin, Letizia Concarri, Seppo Helisalmi, Anne Maria Koivisto, Annakaisa Haapasalo, Franco Deramecourt, Francesca Salani, Nathalie Fievet, Olivier Hanon, Carole Dufouril, Alexis Brice, Karen Ritchie, Bruno Dubois, Hilinka Soininen, Laura Fratiglioni, Lina Keller, Francesco Panza, Didier Hannequin, Paolo Caffarra, Lars Lannfelt, Florence Pasquier, Paola Bosso, Alberto Pilotto, Maria J. Bullido, Paola Bosco, Eliecer Coto, Alberto Lleo, Martin Ingelsson, Caroline Graff, Pascual Sanchez-Juan, Claudine Berr, Stéphanie Debette, Jean-Francois Dartigues, Gael Nicolas, Dominique Campion, Jordi Clarimon, Christine Van Broeckhoven, Jean-François Deleuze, Phillippe Amouyel, Jean-Charles Lambert.

**The GERAD study**

GERAD1 Collaborators: Denise Harold1, Rebecca Sims1, Amy Gerrish1, Jade Chapman1, Valentina Escott-Price1, Nandini Badarinarayan1, Richard Abraham1, Paul Hollingworth1, Marian Hamsher1, Jaspreet Singh Pahwa1, Kimberley Dowzell1, Amy Williams1, Nicola Jones1, Charlene Thomas1, Alexander Stretton1, Angharad Morgan1, Kate Williams1, Sarah Taylor1, Simon Lovestone2, John Powell3, Petroula Proitsi3, Michelle K Lupton3, Carol Brayne4, David C. Rubinsztein5, Michael Gill5, Brian Lawlor6, Aoibhinn Lynch6, Kevin Morgan7, Kristelle Brown7, Peter Passmore8, David Craig9, Bernadette McGuinness9, Janet A Johnston8, Stephen Todd8, Clive Holmes9, David Mann10, A. David Smith11, Seth Love12, Patrick G. Kehoe12, John Hardy13, Rita Guerreiro14,15, Andrew Singleton14, Simon Mead16, Nick Fox17, Martin Rossor17, John Collinge18, Wolfgang Maier18, Frank Jessen18, Reiner Heun18, Britta Schürmann18,19, Alfredo Ramirez18, Tim Becker20, Christine Herold20, André Lacour20, Dmitriy Drichel20, Hendrik van den Bussche21, Isabella Heuser22, Johannes Kornhuber23, Jens Wittfang24, Martin Dicghans25,26, Lutz Frölich27, Harald Hampel28, Michael Hüll29, Dan Rujescu30, Alison Goate31, John S.K. Kauwe32, Carlos Cruhaga33, Petra Nowotny33, John C. Morris33, Kevin Mayo33, Gill Livingston34, Nicholas J. Bass34, Hugh Gurling34, Andrew McQuillin34, Rhian Gwilliam35, Panagiota Deloukas35, Markus M. Nötgen20, Peter Holmans1, Michael O’Donovan1, Michael J.Owen1, Julie Williams1.

1Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Neurosciences and Mental Health Research Institute, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK.
2Department of Psychiatry, Medical Sciences Division, University of Oxford, Oxford, UK. 3Kings College London, Institute of Psychiatry, Department of Neuroscience, De Crespigny Park, Denmark Hill, London, UK. 4Institute of Public Health, University of Cambridge, Cambridge, UK. 5Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. 6Mercers Institute for Research on Aging, University of Oxford, Oxford, UK. 7Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK. 8Clinical Neuroscience Research Group, Greater Manchester Neurosciences Centre, University of Manchester, Salford, UK. 9Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Department of Pharmacology, Mansfield Road, Oxford, UK. 10University of Bristol Institute of Clinical Neurosciences, School of Clinical Sciences, Frenchay Hospital, Bristol, UK. 11Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, Institute of Neurology, UCL, London, UK. 12Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, United States of America. 13Department of
Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK. 16MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. 17Dementia Research Centre, Department of Neurodegenerative Diseases, University College London, Institute of Neurology, London, UK. 18Department of Psychiatry, University of Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany. 19Institute for Molecular Psychiatry, University of Bonn, Bonn, Germany. 20Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany. 21Institute of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Germany. 22Department of Psychiatry, Charité Berlin, Germany. 23Department of Psychiatry, Friedrich-Alexander-University Erlangen-Nürnberg, Germany. 24Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August-University, Göttingen, Germany. 25Institute for Stroke and Dementia Research, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 26Department of Neurology, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 27Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany. 28Institute for Memory and Alzheimer’s Disease and INSERM, Sorbonne Universities, Pierre and Marie Curie University, Paris, France; Institute for Brain and Spinal Cord Disorders (ICM), Department of Neurology, Hospital of Pitié-Salpêtrière, Paris, France. 29Centre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Germany. 30Department of Psychiatry, University of Halle, Halle, Germany. 31Neuroscience Department, Ichahn School of Medicine at Mount Sinai, New York, US. 32Department of Biology, Brigham Young University, Provo, UT, 84602, USA. 33Departments of Psychiatry, Neurology and Genetics, Washington University School of Medicine, St Louis, MO 63110, US. 34Department of Mental Health Sciences, University College London, UK. 35The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

The GR@ACE/DEGESCO consortium

The GR@ACE study group: Abdelnour C1,2, Aguilera N1, Alarcón Martín E1,4, Álvarez I5, Álvarez V6,7, Amer-Ferrer G8, Antequera M4, Antuñes C9, Baquero M10, Bernal M11, Blesa R12, Boada M13, Buiza-Rueda D14, Bulido MJ13,14, Burguera JA10, Calero M15,16, Carrillo F1,2, Carrion-Claro M1,2, Casajeros M1, Clarimón J1, Cruz-Gamero JM4, de Pancorbo MM10, de Rojas I1, del Ser T14, Diez-Fairen M15, Foretta J12, Franco E11, Frank-García A1,14,19, García-Alberca JM10, Garcia Madrona S16, Garcia-Ribas G10, Gómez-Garre P1,2, Hernández I1,3, Hevia M16, Hevia Jesús S1,2, Labrador Espinoza MA1,2, Lage C2,21, Legaz A2,2,2, López de Munáin A2,2, López-Garcia S2,21, Macias D1,2, Manzanares S9,23, Marín M11, Marín-Muñoz J9, Marín T20, Marquié M3, Martín Montes A13,19, Martínez B9, Martínez C7,24, Martínez V9, Martínez-Lage Álvarez P25, Medina M2,14, Mendioroz Iriarte M26, Menéndez-González M17,27, Mir P1,2, Molinuevo JL18, Monté-Rubio G3, Montreal L1, Moreno-Grau S2,23, Orellana A1, Pastor AB15, Pastor P16, Pérez Tur J2,29,30, Periñán-Tocino T1,2, Piñol Ripoll G2,31, Rábano A2,15,32, Real de Asúa D3, Rodrigo S11, Rodríguez-Rodríguez E2,21, Royo JL4, Ruiz A2,23, Sanchez del Valle Díaz R34, Sánchez-Juan P2,21, Sastre J2,23, Solotoongo-Grau O3, Tárraga L2,23, Valero S2,2, Vicente MP6, Vivancos L9 (1. Research Center and Memory clinic Fundació ACE. Institut Català de Neuroècies Aplicades. Universitat Internacional de Catalunya. Barcelona, Spain; 2. CIBERNED, Center for Networked Biomedical Research on Neurodegenerative Diseases, National Institute of Health Carlos III, Ministry of Economy and Competitiveness, Spain; 3. Dep. of Surgery, Biochemistry and Molecular Biology, School of Medicine. University of Málaga. Málaga, Spain; 4. Grupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCHI), Universidad de Santiago de Compostela, Santiago de Compostela, Spain; 5. Fundación Pública Galega de Medicina Xenómica-CIBERER-IDIS, Santiago de Compostela, Spain; 6. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Spain, Hospital Clínico San Carlos, Madrid, Spain; 7. CAEBI, Centro Andaluz de Estudios Bioinformáticos., Sevilla, Spain; 8. Unidad Clínica de Enfermedades Infecciosas y Microbiología. Hospital Universitario de Valme, Sevilla, Spain).

DEGESCO consortium: Adarmes-Gómez AD1,2, Alarcón-Martín E1,4, Álvarez I5, Álvarez V6,7, Amer-Ferrer G8, Antequera M4, Antuñes C9, Baquero M10, Bernal M11, Blesa R12, Boada M13, Buiza-Rueda D14, Bulido MJ2,13,14, Burguera JA10, Calero M15,16, Carrillo F1,2, Carrion-Claro M1,2, Casajeros M1, Clarimón J1, Cruz-Gamero JM4, de Pancorbo MM10, de Rojas I1, del Ser T14, Diez-Fairen M15, Foretta J12, Franco E11, Frank-García A1,14,19, García-Alberca JM10, Garcia Madrona S16, Garcia-Ribas G16, Gómez-Garre P1,2, Hernández I1,3, Hevia M16, Hevia Jesús S1,2, Labrador Espinoza MA1,2, Lage C2,21, Legaz A2,2,2, López de Munáin A2,2, López-Garcia S2,21, Macias D1,2, Manzanares S9,23, Marín M11, Marín-Muñoz J9, Marín T20, Marquié M3, Martín Montes A13,19, Martínez B9, Martínez C7,24, Martínez V9, Martínez-Lage Álvarez P25, Medina M2,14, Mendioroz Iriarte M26, Menéndez-González M1,27, Mir P1,2, Molinuevo JL18, Monté-Rubio G3, Montreal L1, Moreno-Grau S2,23, Orellana A1, Pastor AB15, Pastor P16, Pérez Tur J2,29,30, Periñán-Tocino T1,2, Piñol Ripoll G2,31, Rábano A2,15,32, Real de Asúa D3, Rodrigo S11, Rodríguez-Rodríguez E2,21, Royo JL4, Ruiz A2,23, Sanchez del Valle Díaz R34, Sánchez-Juan P2,21, Sastre J2,23, Solotoongo-Grau O3, Tárraga L2,23, Valero S2,2, Vicente MP6, Vivancos L9 (1. Research Center and Memory clinic Fundació ACE. Institut Català de Neuroècies Aplicades. Universitat Internacional de Catalunya. Barcelona, Spain; 2. CIBERNED, Center for Networked Biomedical Research on Neurodegenerative Diseases, National Institute of Health Carlos III, Ministry of Economy and Competitiveness, Spain; 3. Dep. of Surgery, Biochemistry and Molecular Biology, School of Medicine. University of Málaga. Málaga, Spain; 4. Grupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCHI), Universidad de Santiago de Compostela, Santiago de Compostela, Spain; 5. Fundación Pública Galega de Medicina Xenómica-CIBERER-IDIS, Santiago de Compostela, Spain; 6. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Spain, Hospital Clínico San Carlos, Madrid, Spain; 7. CAEBI, Centro Andaluz de Estudios Bioinformáticos., Sevilla, Spain; 8. Unidad Clínica de Enfermedades Infecciosas y Microbiología. Hospital Universitario de Valme, Sevilla, Spain).

www.aging-us.com 9311 AGING
CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Spain; 3. Research Center and Memory clinic Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya. Barcelona, Spain; 4. Dep. of Surgery, Biochemistry and Molecular Biology, School of Medicine. University of Málaga. Málaga, Spain; 5. Fundació per la Recerca Biomèdica i Social Mutua Terrassa, and Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, University of Barcelona School of Medicine, Terrassa, Barcelona, Spain; 6. Laboratorio de Genética Hospital Universitario Central de Asturias, Oviedo; 7. Instituto de Investigación Biosanitaria del Principado de Asturias (ISPA); 8. Department of Neurology, Hospital Universitario Son Espases, Palma, Spain; 9. Unidad de Demencias. Hospital Clínico Universitario Virgen de la Arrixaca; 10. Servei de Neurologia, Hospital Universitari i Politécnic La Fe; 11. Unidad de Demencias, Servicio de Neurología y Neurofisiología. Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain; 12. Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; 13. Centro de Biología Molecular Severo Ochoa (C.S.I.C.-U.A.M.), Universidad Autónoma de Madrid, Madrid, Spain; 14. Instituto de Investigacion Sanitaria de la Región de Murcia; 15. Instituto de Investigación Sanitarias de la Región de Murcia; 16. Instituto de Salud Carlos III (ISCIII), Madrid, Spain; 17. Hospital Universitario Ramón y Cajal; Madrid, Spain; 18. BIOMICS. País Vasco; Centro de Investigación Lascaray. Universidad del País Vasco UPV/EHU; 19. Neurology Service, Hospital Universitario La Paz (UAM), Madrid, Spain; 20. Alzheimer Research Center and Memory Clinic. Andalusian Institute for Neuroscience. Málaga, Spain; 21. Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain; 22. Hospital Donostia de San Sebastián; 23. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia; 24. Servicio de Neurología -Hospital de Cabuerniga-Gijón; 25. Centro de Investigación y Terapias Avanzadas. Fundación CITAlzheimer; 26. Navarrabiomed; 27. Servicio de Neurología -Hospital Universitario Central de Asturias, Oviedo; 28. Barcelona ßeta Brain Research Center – Fundació Pasqual Maragall; 29. Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC; 30. Unidad Mixta de Neurología Genética. Instituto de Investigación Sanitaria La Fe; 31. Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Institut de Recerca Biomèdica de Lleida (IRBLLeida), Lleida, España. 32. BT-CIEN; 33. Hospital Universitario La Princesa, Madrid, Spain; 34. Hospital Clínic Barcelona.

REFERENCES

1. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011; 43:436–41. https://doi.org/10.1038/ng.801 PMID:21460841

2. Proitsi P, Lupton MK, Velayudhan L, Newhouse S, Fogh I, Tsolaki M, Daniilidou M, Pritchard M, Kloszewska I, Soininen H, Meccoci P, Vellas B, Williams J, et al. Alzheimer’s Disease Neuroimaging Initiative, and GERAD1 Consortium. Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: A Mendelian randomization analysis. PLoS Med. 2014; 11:e1001713. https://doi.org/10.1371/journal.pmed.1001713 PMID:25226301

3. Lourdusamy A, Newhouse S, Lunnon K, Proitsi P, Powell J, Hodges A, Nelson SK, Stewart A, Williams S, Kloszewska I, Meccoci P, Soininen H, Tsolaki M, et al. AddNeuroMed Consortium. Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: A Mendelian randomization analysis. PLoS Med. 2014; 11:e1001713. https://doi.org/10.1371/journal.pmed.1001713 PMID:25226301

4. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989; 129:687–702. PMID:26469171

5. Psaty BM, O’Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JC, Boerwinkle E, and CHARGE Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009; 2:73–80. https://doi.org/10.1161/CIRCGENETICS.108.289747 PMID:20031568

6. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, Debette S, Lumley T, Folsom AR, van den Herik EG, Bos MJ, Beiser A, Cushman M, et al. Genomewide association studies of stroke. N Engl J Med. 2009; 360:1718–28. https://doi.org/10.1056/NEJMoa0900094 PMID:19369658
7. Fried LP, Borhani NO, Enright P, Furbeger CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1:263–76. https://doi.org/10.1016/1047-2797(91)90005-W PMID:1669507

8. 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology. 2003; 22:316–25. https://doi.org/10.1159/000072920 PMID:14598854

9. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975; 4:518–25. https://doi.org/10.1016/0091-7435(75)90037-7 PMID:1208363

10. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D’Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O’Donnell CJ, Vasan RS, Wolf PA, Levy D. The Third Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007; 165:1328–35. https://doi.org/10.1093/aje/kwm021 PMID:17372189

11. Filippi N, Rao A, Wetten S, Gibson RA, Borrie M, Guzman D, Kertesz A, Loy-English I, Williams J, Nichols T, Whitter B, Matthews PM. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer’s disease. Neuroimage. 2009; 44:724–28. https://doi.org/10.1016/j.neuroimage.2008.10.003 PMID:19013250

12. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008; 65:45–53. https://doi.org/10.1001/archneur.2007.3 PMID:17998437

13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7:263–69. https://doi.org/10.1016/j.jalz.2011.03.005 PMID:21514250

14. Moreno-Grau S, de Rojas I, Hernández I, Quintela I, Montrealar L, Alegret M, Hernández-Olazaragüe B, Madrid L, González-Perez A, Maroñas O, Rosende-Roca M, Mauleón A, Vargas L, et al, GR@ACE consortium, DEGESCO consortium, and Alzheimer’s Disease Neuroimaging Initiative. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer’s disease and three causality networks: The GR@ACE project. Alzheimers Dement. 2019; 15:1333–47. https://doi.org/10.1016/j.jalz.2019.06.4950 PMID:31473137

15. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglia GD, Ertekin-Taner N, Crook JE, Dickson DW, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease. Nat Genet. 2009; 41:192–98. https://doi.org/10.1038/ng.305 PMID:19136949

16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34:939–44. https://doi.org/10.1212/WNL.34.7.939 PMID:6610841

17. Gayán J, Galan JJ, González-Pérez A, Sáez ME, Martínez-Larrad MT, Zabena C, Rivero MC, Salinas A, Ramírez-Lorca R, Morón FJ, Royo JL, Moreno-Rey C, Velasco J, et al. Genetic structure of the Spanish population. BMC Genomics. 2010; 11:326. https://doi.org/10.1186/1471-2164-11-326 PMID:20500880

18. Antúnez C, Boada M, González-Pérez A, Gayán J, Ramírez-Lorca R, Marín J, Hernández I, Moreno-Rey C, Morón FJ, López-Arrieta J, Mauleón A, Rosende-Roca M, Noguera-Perea F, et al, and Alzheimer’s Disease Neuroimaging Initiative. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease. Genome Med. 2011; 3:33. https://doi.org/10.1186/gm249 PMID:21627779

19. Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R, and National Institute on Aging Late-Onset Alzheimer’s Disease Family Study Group. Analyses of the National Institute on Aging Late-Onset Alzheimer’s Disease Family Study: implication of additional loci. Arch Neurol. 2008; 65:1518–26. https://doi.org/10.1001/archneur.65.11.1518 PMID:19001172

20. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012; 9:628–45. https://doi.org/10.2174/156720512801322573 PMID:22471860

21. Hofman A, Brusselle GG, Darwih Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CC,
Nijsten TE, Peeters RP, Stricker BH, Tiemeier HW, Uitterlinden AG, Vernooij MW. The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol. 2015; 30:661–708. https://doi.org/10.1007/s10654-015-0082-x PMID:26386597

22. Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, Kieboom BC, Klaver CC, de Knecht RJ, Luik AI, Nijsten TE, Peeters RP, van Rooij FJ, et al. Objectives, design and main findings until 2020 from the Rotterdam Study. Eur J Epidemiol. 2020; 35:483–517. https://doi.org/10.1007/s10654-020-00640-5 PMID:32367290

23. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, et al. GAB2 alleles modify Alzheimer’s risk in APOE epsilon4 carriers. Neuron. 2007; 54:713–20. https://doi.org/10.1016/j.neuron.2007.05.022 PMID:17553421
Supplementary Figures

Supplementary Figure 1. Stage I meta-analysis manhattan and QQ plots (all strata).

Supplementary Figure 2. Stage II meta-analysis manhattan and QQ plots (all strata).
Supplementary Figure 3. Stage III meta-analysis manhattan and QQ plots (all strata).

Supplementary Figure 4. Stage IV meta-analysis manhattan and QQ plots (all strata).
Supplementary Figure 5. Stage I-IV meta-analysis manhattan and QQ plots (all strata).

CDC42EP5(+ 23.3kb) | KIR3DX1(- 36.19kb) | LAIR locus(+ 131kb, -6.293kb) | LENS locus (+ 30kb) | LILR locus (+ -100kb, +180kb) | TTVH1(+ +60kb)

Supplementary Figure 6. Sex stratified meta-analysis manhattan and QQ plots.
Supplementary Figure 7. APOE and sex stratified meta-analysis manhattan and QQ plots.
Supplementary Figure 8. RRA integrative analysis in blood: enrichment analysis for (A) common genes, (B) APOE2, (C) APOE3, (D) APOE4 specific candidates.
Supplementary Figure 9. RRA integrative analysis in cortex: enrichment analysis (A) common genes, (B) APOE2, (C) APOE3, (D) APOE4 specific candidates.
Supplementary Figure 10. Blood proteomics heatmap for RRA blood candidates (ADDN dataset, all strata).
Supplementary Figure 11. Protein expression of relevant RRA blood candidates by APOE stratum and case status.
Supplementary Figure 12. Cortex proteomics heatmap for RRA cortex candidates (meta-analysis, all strata).
Supplementary Figure 13. Cortex snRANseq heatmap for RRA candidates shared by the three APOE strata: (A) Unstratified, (B) APOE2, (C) APOE3, (D) APOE4 AD cases vs controls.
Supplementary Figure 14. Cortex snRANseq heatmap for APOE2 RRA cortex candidates.
Supplementary Figure 15. Cortex snRANseq heatmap for APOE3 RRA cortex candidates.
Supplementary Figure 16. Cortex snRANseq heatmap for APOE4 RRA cortex candidates.
Supplementary Tables

Please browse Full Text version to see the data of Supplementary Tables 1–39.

Supplementary Table 1. Stage I-III APOE2 stratified meta-analysis results (p<10^{-4}).
Supplementary Table 2. Stage I-III APOE3 stratified meta-analysis results (p<10^{-4}).
Supplementary Table 3. Stage I-III APOE4 stratified meta-analysis results (p<10^{-4}).
Supplementary Table 4. Stage I-IV APOE2 stratified meta-analysis results (p<10^{-4}).
Supplementary Table 5. Stage I-IV APOE3 stratified meta-analysis results (p<10^{-4}).
Supplementary Table 6. Stage I-IV APOE4 stratified meta-analysis results (p<10^{-4}).
Supplementary Table 7. Sex stratified meta-analysis (males).
Supplementary Table 8. Sex stratified meta-analysis (females).
Supplementary Table 9. APOE and sex stratified analysis: APOE2 males meta-analysis results (p<10^{-4}).
Supplementary Table 10. APOE and sex stratified analysis: APOE3 males meta-analysis results (p<10^{-4}).
Supplementary Table 11. APOE and sex stratified analysis: APOE4 males meta-analysis results (p<10^{-4}).
Supplementary Table 12. APOE and sex stratified analysis: APOE2 females meta-analysis results (p<10^{-4}).
Supplementary Table 13. APOE and sex stratified analysis: APOE3 females meta-analysis results (p<10^{-4}).
Supplementary Table 14. APOE and sex stratified analysis: APOE4 females meta-analysis results (p<10^{-4}).
Supplementary Table 15. Stage I-III APOE2 stratified meta-analysis gene level results.
Supplementary Table 16. Stage I-III APOE3 stratified meta-analysis gene level results.
Supplementary Table 17. Stage I-III APOE4 stratified meta-analysis gene level results.
Supplementary Table 18. Stage I-III stratified gene level meta-analysis results (Stage I-II) for known AD genes (all strata).
Supplementary Table 19. Differential expression analysis in blood: APOE2 stratum.
Supplementary Table 20. Differential expression analysis in blood: APOE3 stratum.
Supplementary Table 21. Differential expression analysis in blood: APOE4 stratum.
Supplementary Table 22. Differential expression analysis in cortex: APOE2 stratum.
Supplementary Table 23. Differential expression analysis in cortex: APOE3 stratum.
Supplementary Table 24. Differential expression analysis in cortex: APOE4 stratum.
Supplementary Table 25. RRA integrative analysis in blood: APOE2 stratum.
Supplementary Table 26. RRA integrative analysis in blood: APOE3 stratum.
Supplementary Table 27. RRA integrative analysis in blood: APOE4 stratum.
Supplementary Table 28. RRA integrative analysis in cortex: APOE2 stratum.
Supplementary Table 29. RRA integrative analysis in cortex: APOE3 stratum.
Supplementary Table 30. RRA integrative analysis in cortex: APOE4 stratum.
Supplementary Table 31. RRA integrative analysis in blood: enrichment analysis APOE2 stratum.
Supplementary Table 32. RRA integrative analysis in blood: enrichment analysis APOE3 stratum.
Supplementary Table 33. RRA integrative analysis in blood: enrichment analysis APOE4 stratum.
Supplementary Table 34. RRA integrative analysis in cortex: enrichment analysis APOE2 stratum.
Supplementary Table 35. RRA integrative analysis in cortex: enrichment analysis APOE3 stratum.
Supplementary Table 36. RRA integrative analysis in cortex: enrichment analysis APOE4 stratum.
Supplementary Table 37. Blood proteomics differential expression results (all strata).
Supplementary Table 38. Cortex proteomics meta-analysis (all strata).
Supplementary Table 39. Cortex snRNAseq differential expression analysis.